Author: "Noémie Saut" / Topic: biology - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Noémie Saut"' showing total 39 results

Start Over Author "Noémie Saut" Topic biology

39 results on '"Noémie Saut"'

1. GATA1 pathogenic variants disrupt MYH10 silencing during megakaryopoiesis

Author: Timothée Bigot, Marie Loosveld, Noémie Saut, Paul Saultier, Céline Falaise, Pierre-Emmanuel Morange, Sandrine Cabantous, Franck Peiretti, Johannes van Agthoven, Jean-Claude Bordet, Denis Bernot, Delphine Potier, Dominique Payet-Bornet, Matthias Canault, Michel Pucéat, Marie-Christine Alessi, Marjorie Poggi, Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Pédiatrie et oncologie pédiatrique [Hôpital de la Timone - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Marseille medical genetics - Centre de génétique médicale de Marseille (MMG), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital de la Timone [CHU - APHM] (TIMONE), AUTRES, Massachusetts General Hospital [Boston], Harward Medical School, Centre d'Immunologie de Marseille - Luminy (CIML), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), and DUMENIL, Anita
Subjects: Blood Platelets, [SDV]Life Sciences [q-bio], MYH10, Biology, Thrombopoiesis, 03 medical and health sciences, 0302 clinical medicine, Transcription (biology), GATA1, Gene expression, Gene silencing, Humans, GATA1 Transcription Factor, Gene Silencing, Transcription factor, Gene, 030304 developmental biology, Zinc finger, Genetics, 0303 health sciences, Nonmuscle Myosin Type IIB, Myosin Heavy Chains, Intron, Hematology, Thrombocytopenia, 3. Good health, [SDV] Life Sciences [q-bio], functional variants, platelets, downstream targets, Megakaryocytes, 030215 immunology, Transcription Factors
Abstract: International audience; BackgroundGATA1 is an essential transcription factor for both polyploidization and megakaryocyte (MK) differentiation. The polyploidization defect observed in GATA1 variant carriers is not well understood.ObjectiveTo extensively phenotype two pedigrees displaying different variants in the GATA1 gene and determine if GATA1 controls MYH10 expression levels, a key modulator of MK polyploidization.MethodA total of 146 unrelated propositi with constitutional thrombocytopenia were screened on a multigene panel. We described the genotype-phenotype correlation in GATA1 variant carriers and investigated the effect of these novel variants on MYH10 transcription using luciferase constructs.ResultsThe clinical profile associated with the p.L268M variant localized in the C terminal zinc finger was unusual in that the patient displayed bleeding and severe platelet aggregation defects without early-onset thrombocytopenia. p.N206I localized in the N terminal zinc finger was associated, on the other hand, with severe thrombocytopenia (15G/L) in early life. High MYH10 levels were evidenced in platelets of GATA1 variant carriers. Analysis of MKs anti-GATA1 chromatin immunoprecipitation-sequencing data revealed two GATA1 binding sites, located in the 3′ untranslated region and in intron 8 of the MYH10 gene. Luciferase reporter assays showed their respective role in the regulation of MYH10 gene expression. Both GATA1 variants significantly alter intron 8 driven MYH10 transcription.ConclusionThe discovery of an association between MYH10 and GATA1 is a novel one. Overall, this study suggests that impaired MYH10 silencing via an intronic regulatory element is the most likely cause of GATA1-related polyploidization defect.
Published: 2021

2. GATA1 pathogenic variants disrupt MYH10 silencing during megakaryopoiesis

Author: Marie Loosveld, Céline Falaise, Matthias Canault, Noémie Saut, Marjorie Poggi, Paul Saultier, Pierre Morange, Marie-Christine Alessi, Michel Pucéat, Franck Peiretti, J Von Agthoven, Sandrine Cabantous, Denis Bernot, and JC Bordet
Subjects: MYH10, Gene silencing, GATA1, Biology, Cell biology, Megakaryopoiesis
Published: 2021

3. ABO blood group, glycosyltransferase activity and risk of Venous Thrombosis

Author: Pierre-Emmanuel Morange, Jacques Chiaroni, Pascal Bailly, Noémie Saut, Manal Ibrahim Kosta, David-Alexandre Trégouët, Pierre Suchon, Louisa Goumidi, and Monique Silvy
Subjects: congenital, hereditary, and neonatal diseases and abnormalities, medicine.medical_specialty, biology, Chemistry, Plasma levels, medicine.disease, Glycosyltransferase activity, Venous thrombosis, chemistry.chemical_compound, Endocrinology, Von Willebrand factor, hemic and lymphatic diseases, Internal medicine, Galactose, AGT activity, ABO blood group system, parasitic diseases, Glycosyltransferase, biology.protein, medicine
Abstract: IntroductionABO blood group influence the risk of venous thrombosis (VT) by modifying A and B glycosyltransferases (AGT and BGT) activities that further modulates Factor VIII (FVIII) and von Willebrand Factor (VWF) plasma levels. The aim of this work was to evaluate the association of plasma GTs activities with VWF/FVIII plasma levels and VT risk in a case-control study.Materials and Methods420 cases were matched with 420 controls for age and ABO blood group. GT activities in plasma were measured using the quantitative transfer of tritiated N-acetylgalactosamine or galactose to the 2’-fucosyl-lactose and expressed in disintegration per minute/30µL of plasma and 2 hours of reaction (dpm/30µL/2H). FVIII and VWF plasma levels were respectively measured using human FVIII-deficient plasma in a 1-stage factor assay and STA LIATEST VWF (Diagnostica Stago).ResultsA and B GT activities were significantly lower in cases than in controls (8119±4027 vs 9682±4177 dpm/30µL/2H, p=2.03 × 10−5, and 4931±2305 vs 5524±2096 dpm/30µL/2H, p=0.043 respectively). This association was observed whatever the ABO blood groups. The ABO A1 blood group was found to explain∼80% of AGT activity. After adjusting for ABO blood groups, AGT activity was not correlated to VWF/FVIII plasma levels. Conversely, there was a moderate correlation (ρ∼0.30) between BGT activity and VWF/ FVIII plasma levels in B blood group carriers.ConclusionThis work showed, for the first time, that GT activities were decreased in VT patients in comparison to controls with the same ABO blood group. The biological mechanisms responsible for this association remained to be determined.
Published: 2020

4. Bernard–Soulier syndrome: first human case due to a homozygous deletion of GP9 gene

Author: Florentine Garaix, Dorsaf Ghalloussi, Michel Tsimaratos, Caroline Rousset‐Rouvière, Noémie Saut, Marie-Christine Alessi, Hervé Chambost, Paul Saultier, Véronique Baccini, Cornel Popovici, Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hôpital de la Timone [CHU - APHM] (TIMONE), Laboratoire d'hématologie biologique [Hôpital de la Timone - Hôpital Nord - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Service de pédiatrie, d'hématologie et d'oncologie [Hôpital de La Timone - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), and Prémilleux, Annick
Subjects: Male, Platelet aggregation, [SDV]Life Sciences [q-bio], Platelet disorder, thrombocytopenia, platelet membrane, Biology, platelet genetic diseases, Bernard–Soulier syndrome, 03 medical and health sciences, 0302 clinical medicine, Bone Marrow, medicine, Humans, platelet disorders, Gene, Sequence Deletion, 030304 developmental biology, 0303 health sciences, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Infant, Newborn, Bernard-Soulier Syndrome, Hematology, medicine.disease, Pedigree, 3. Good health, [SDV] Life Sciences [q-bio], Platelet Glycoprotein GPIb-IX Complex, platelet aggregation, Immunology, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, 030215 immunology
Abstract: International audience; Bernard–Soulier Syndrome (BSS) is a rare (1:1 million) hereditary bleeding disorder caused by defects in the platelet glycoprotein (GP)‐Ib/IX/V complex, a receptor for von Willebrand factor (VWF) and thrombin (Lanza, 2006; Berndt & Andrews, 2011). Patients typically present with epistaxis, petechial or gingival bleeding with onset already in infancy. They present with macrothrombocytopenia and their platelets do not agglutinate in response to ristocetin, while maintaining a normal aggregation in response to a variety of aggregating agents. GPIb/IX/V complex consists of two GPIbα and four GPIbβ subunits stabilized by disulphide bonds (Luo et al., 2007). This heterodimer is non‐covalently associated with two GPIX and one GPV subunits. The N‐terminal residues of GPIbα form seven leucine‐rich repeats (LRRs) and include the binding sites for VWF and thrombin. BSS is due to biallelic loss‐of‐function pathogenic variants (deletions, insertions and nonsense mutations) in GPIBA, GPIBB or GP9 genes encoding GPIb/IX/V complex (Savoia et al., 2014). However, so far, no mutation in GP5 causing BSS has been reported yet. Most of the mutations prevent the formation of the complex or trafficking it through the endoplasmic reticulum and Golgi apparatus and alter receptor expression (Salles et al., 2008; Savoia et al., 2011; Nurden et al., 2012).
Published: 2020

5. ABO blood group, glycosyltransferase activity and risk of venous thromboembolism

Author: Pierre-Emmanuel Morange, Louisa Goumidi, Monique Silvy, Noémie Saut, Jacques Chiaroni, Manal Ibrahim-Kosta, David-Alexandre Trégouët, Pierre Suchon, Pascal Bailly, Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Biologie des antigènes de groupes sanguins humains, Institut National de la Santé et de la Recherche Médicale (INSERM), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Etablissement Francais du Sang, France APR-2014-17
Subjects: Glycosyltransferase activity, medicine.medical_specialty, congenital, hereditary, and neonatal diseases and abnormalities, 030204 cardiovascular system & hematology, Factor VIII and von Willebrand factor, ABO Blood-Group System, 03 medical and health sciences, 0302 clinical medicine, Von Willebrand factor, Internal medicine, ABO blood group system, AGT activity, hemic and lymphatic diseases, parasitic diseases, Glycosyltransferase, von Willebrand Factor, Venous thrombosis, medicine, Humans, Factor VIII, biology, business.industry, ABO blood group, Glycosyltransferases, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, Plasma levels, Venous Thromboembolism, medicine.disease, Endocrinology, VINTAGE, 030220 oncology & carcinogenesis, Case-Control Studies, biology.protein, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, Venous thromboembolism
Abstract: International audience; Introduction: ABO blood group influence the risk of venous thromboembolism (VTE) by modifying A and B glycosyltransferases (AGT and BGT) activities that further modulates Factor VIII (FVIII) and von Willebrand Factor (VWF) plasma levels. The aim of this work was to evaluate the association of plasma GTs activities with VWF/FVIII plasma levels and VTE risk in a case-control study.Materials and methods: 420 cases were matched with 420 controls for age and ABO blood group. GT activities in plasma were measured using the quantitative transfer of tritiated N-acetylgalactosamine or galactose to the 2′-fucosyl-lactose and expressed in disintegration per minute/30 μL of plasma and 2 h of reaction (dpm/30 μL/2H). FVIII and VWF plasma levels were respectively measured using human FVIII-deficient plasma in a 1-stage factor assay and STA LIATEST VWF (Diagnostica Stago).Results: A and B GT activities were significantly lower in cases than in controls (8119 ± 4027 vs 9682 ± 4177 dpm/30 μL/2H, p = 2.03 × 10 −5, and 4931 ± 2305 vs 5524 ± 2096 dpm/30 μL/2H, p=0.043 respectively). This association was observed whatever the ABO blood groups. The ABO A1 blood group was found to explain~80% of AGT activity. After adjusting for ABO blood groups, AGT activity was not correlated to VWF/FVIII plasma levels. Conversely, there was a moderate correlation (ρ ~ 0.30) between BGT activity and VWF/ FVIII plasma levels in B blood group carriers.Conclusion: Work showed, for the first time, that GT activities were decreased in VTE patients in comparison to controls with the same ABO blood group. The biological mechanisms responsible for this association remained to be determined.
Published: 2020

6. A Genome Wide Association Study on plasma FV levels identified PLXDC2 as a new modifier of the coagulation process

Author: Jean-François Deleuze, Pierre-Emmanuel Morange, Florian Thibord, Manal Ibrahim-Kosta, Per Eriksson, Lise M Hardy, Noémie Saut, Mete Civelek, Anne-Sophie Pulcrano-Nicolas, Louisa Goumidi, David-Alexandre Trégouët, Wilfried Le Goff, Sorbonne Université (SU), Université de Bordeaux (UB), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital de la Timone [CHU - APHM] (TIMONE), Aix Marseille Université (AMU), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), University of Virginia, Karolinska Institutet [Stockholm], University Hospital, Centre National de Génotypage (CNG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Fondation Jean Dausset, Assistance Publique - Hôpitaux de Marseille (APHM), ANR-10-LABX-0013, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], and Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Subjects: Adult, Male, Cell type, In silico, Receptors, Cell Surface, Locus (genetics), Genome-wide association study, 030204 cardiovascular system & hematology, Polymorphism, Single Nucleotide, Transcriptome, 03 medical and health sciences, 0302 clinical medicine, computational biology, Cell Line, Tumor, Genetic variation, Gene expression, Humans, genetics, coagulation factor, Blood Coagulation, Aged, Genetics, factor V, biology, Factor V, biomarkers, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, Middle Aged, 3. Good health, Phenotype, Gene Expression Regulation, Factor X, Hepatocytes, biology.protein, Female, Prothrombin, Genome-Wide Association Study
Abstract: International audience; Background Factor V (FV) is a circulating protein primarily synthesized in the liver, and mainly present in plasma. It is a major component of the coagulation process. Objective To detect novel genetic loci participating to the regulation of FV plasma levels. Methods We conducted the first Genome Wide Association Study on FV plasma levels in a sample of 510 individuals and replicated the main findings in an independent sample of 1156 individuals. Results In addition to genetic variations at the F5 locus, we identified novel associations at the PLXDC2 locus, with the lead PLXDC2 rs927826 polymorphism explaining ~3.7% (P = 7.5 × 10−15 in the combined discovery and replication samples) of the variability of FV plasma levels. In silico transcriptomic analyses in various cell types confirmed that PLXDC2 expression is positively correlated to F5 expression. SiRNA experiments in human hepatocellular carcinoma cell line confirmed the role of PLXDC2 in modulating factor F5 gene expression, and revealed further influences on F2 and F10 expressions. Conclusion Our study identified PLXDC2 as a new molecular player of the coagulation process.
Published: 2019

7. Minor allele of the factor V K858R variant protects from venous thrombosis only in non-carriers of factor V Leiden mutation

Author: Céline Derbois, Noémie Saut, Philippe Amouyel, Stéphanie Debette, Louisa Goumidi, Elisabetta Castoldi, Manal Ibrahim-Kosta, David M. Smadja, Marine Germain, P. van Doorn, Pierre Morange, Etienne Patin, Marie-Christine Alessi, Pierre Suchon, Robert Olaso, David A. Tregouet, Francis Couturaud, Jean-François Deleuze, Florian Thibord, Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire d'hématologie biologique [Hôpital de la Timone - Hôpital Nord - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Département de Médecine Interne et Pneumologie [Brest] (DMIP - Brest), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), Innovations thérapeutiques en hémostase (IThEM - U1140), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'hématologie biologique [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Université Paris Descartes - Paris 5 (UPD5), Université Sorbonne Paris Cité (USPC), Centre National de Génotypage (CNG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Sorbonne Université (SU), Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 (RID-AGE), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre National de Recherche en Génomique Humaine (CNRGH), Maastricht University [Maastricht], Centre de Bioinformatique, Biostatistique et Biologie Intégrative (C3BI), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Génétique Evolutive Humaine - Human Evolutionary Genetics, The authors would like to thank three research programs managed by the National Research Agency (ANR) as part of the French Investment for the Future initiative genetic investigations: the GENMED Laboratory of Excellence on Medical Genomics (ANR-10-LABX-0013), the French Clinical Research Infrastructure Network on Venous Thrombo-Embolism (F-CRIN INNOVTE) and the ICAN Institute for Cardiometabolism and Nutrition (ANR-10-IAHU-05) who partially supported performing genetic investigations in the MARTHA GWAS, MARTHA12, EDITH and FARIVE studies. TF was financially supported by a PhD grant from the GENMED Laboratory of Excellence on Medical Genomics (ANR-10-LABX-0013). vDP was supported by grant nr. 2014-1 from the Dutch Thrombosis Foundation. The present project was supported by a grant from CSL Behring., ANR-10-LABX-0013,GENMED,Medical Genomics(2010), ANR-10-INBS-0003,F-CRIN,Plateforme Nationale d'Infrastructures de Recherche Clinique(2010), ANR-10-IAHU-0005,ICAN,Institut de Cardiologie-Métabolisme-Nutrition(2010), Biochemie, RS: CARIM - R1 - Thrombosis and haemostasis, RS: CARIM - R1.01 - Blood proteins & engineering, RS: Carim - B01 Blood proteins & engineering, Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Centre recherche en CardioVasculaire et Nutrition (C2VN), Université de Brest (UBO), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement (Inserm U1167 - RID-AGE - Institut Pasteur), ANR: PREFI-10-LABX-13/10-LABX-0013,GENMED,Medical Genomics(2010), ANR-10-INBS-03-01/10-INBS-0003,F-CRIN,Plateforme Nationale d'Infrastructures de Recherche Clinique(2010), ANR-10-IAHU-0005/10-IAHU-0005,ICAN,ICAN(2010), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), and Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)
Subjects: 0301 basic medicine, Male, lcsh:Medicine, Genome-wide association study, polymorphisme, PATHWAY, 0302 clinical medicine, COAGULATION-FACTOR-V, lcsh:Science, Venous Thrombosis, RISK, Multidisciplinary, biology, Factor V, DEFECTS, Venous thrombosis, Female, France, medicine.drug, medicine.medical_specialty, Heterozygote, B-DOMAIN, Médecine humaine et pathologie, Article, 03 medical and health sciences, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, medicine, Factor V Leiden, Humans, Allele, GENOME-WIDE ASSOCIATION, coagulation, facteur viii, Alleles, Genetic Association Studies, business.industry, lcsh:R, allèle, medicine.disease, GENE, Minor allele frequency, 030104 developmental biology, Endocrinology, Amino Acid Substitution, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, Case-Control Studies, biology.protein, lcsh:Q, Human health and pathology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Activated protein C resistance, business, 030217 neurology & neurosurgery, Protein C, RESISTANCE, thrombose veineuse
Abstract: Factor V serves an important role in the regulation of blood coagulation. The rs6025 (R534Q) and rs4524 (K858R) polymorphisms in the F5 gene, are known to influence the risk of venous thrombosis. While the rare Q534 (factor V Leiden) allele is associated with an increased risk of venous thrombosis, the minor R858 allele is associated with a lower risk of disease. However, no study has deeply examined the cumulative impact of these two variations on venous thrombosis risk. We study the association of these polymorphisms with the risk of venous thrombosis in 4 French case-control populations comprising 3719 patients and 4086 controls. We demonstrate that the Q534 allele has a dominant effect over R858. Besides, we show that in individuals not carrying the Q534 allele, the protective effect of the R858 allele acts in a dominant mode. Thrombin generation-based normalized activated protein C sensitivity ratio was lower in the 858R/R homozygotes than in the 858K/K homozygotes (1.92 ± 1.61 vs 2.81 ± 1.57, p = 0.025). We demonstrate that the R858 allele of the F5 rs4524 variant protects from venous thrombosis only in non-carriers of the Q534 allele of the F5 rs6025. Its protective effect is mediated by reduced factor VIII levels and reduced activated protein C resistance.
Published: 2019

8. Human thymopoiesis is influenced by a common genetic variant within the TCRA-TCRD locus

Author: Lluis Quintana-Murci, Marine Germain, Magnus Fontes, Antoine Toubert, Itauá Leston Araujo, David-Alexandre Trégouët, James P. Di Santo, Emmanuel Clave, Corinne Douay, Silvia Lopez-Lastra, Milena Hasan, Bruno Charbit, Noémie Saut, Breno Luiz Melo-Lima, Darragh Duffy, Cécile Alanio, Jacob Bergstedt, Alejandra Urrutia, Cameron Ross MacPherson, Yan Li, Etienne Patin, Pierre-Emmanuel Morange, Matthew L. Albert, Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7), Alloimmunité-Autoimmunité-Transplantation (A2T), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Immunobiologie des Cellules dendritiques, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche Translationnelle - Center for Translational Science (CRT), Institut Pasteur [Paris] (IP), Génétique Evolutive Humaine - Human Evolutionary Genetics, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Centre de Bioinformatique, Biostatistique et Biologie Intégrative (C3BI), Lund University [Lund], Genentech, Inc., Genentech, Inc. [San Francisco], Immunité Innée - Innate Immunity, Laboratoire d'hématologie biologique [Hôpital de la Timone - Hôpital Nord - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), International Group for Data Analysis (IGDA), Service d'Immunologie et d'Histocompatibilité, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), This work was supported by the French government’s Invest in the Future Program, managed by the Agence Nationale de la Recherche (ANR, 10-LABX-69-01). I.L.A. was a recipient of the Science without Borders PhD program from Brazil Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). J.B. is a member of the Lund Center for Control of Complex Engineering Systems (LCCC) Linnaeus Center and the Excellence Center at Linköping-Lund in Information Technology (ELLIT) Excellence Center at Lund University and is supported by the ELLIIT Excellence Center. J.P.D.S., Y.L., and S.L.-L. received funding from Institut Pasteur, INSERM, the Laboratoire d’Excellence REVIVE. A.T. and E.C. received funding from ANR grant PriCelAge (ANR-14-CE14-0030-01). Genetic investigations in the MARTHA study were supported by the GENMED Laboratory of Excellence on Medical Genomics (ANR-10-LABX-0013), We thank J. Fellay, P. Scepanovic, and C. A. W. Thorball for support with genetic analysis and J.-M. Doisne, G. M. Ranson, and H. Strick-Marchand for support with humanized mouse experiments. We thank V. Asnafi, E. Macintyre, A. Cieslak, and I. André-Schmutz for helpful discussions. We also thank the Centre d’Immunologie Humaine (Institut Pasteur, Paris, France) for support., ANR-14-CE14-0030,PriCelAge,Induction de réponses cellulaires T avec l'âge avancé(2014), ANR-10-LABX-0013,GENMED,Medical Genomics(2010), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Diderot - Paris 7 (UPD7), Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche Translationnelle (CRT), Institut Pasteur [Paris], Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Immunité Innée, Centre recherche en CardioVasculaire et Nutrition (C2VN), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP]-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), ANR-14-CE14-0030,PriCelAge,Induction de réponses cellulaires T avec l’âge avancé(2014), ANR: PREFI-10-LABX-13/10-LABX-0013,GENMED,Medical Genomics(2010), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], and Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Subjects: 0301 basic medicine, education.field_of_study, T-cell receptor excision circles, T cell, Population, Genome-wide association study, Locus (genetics), General Medicine, Biology, 3. Good health, Transplantation, 03 medical and health sciences, Haematopoiesis, Thymocyte, 030104 developmental biology, 0302 clinical medicine, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Immunology, medicine, [SDV.IMM]Life Sciences [q-bio]/Immunology, education
Abstract: International audience; The thymus is the primary lymphoid organ where naïve T cells are generated; however, with the exception of age, the parameters that govern its function in healthy humans remain unknown. We characterized the variability of thymic function among 1000 age- and sex-stratified healthy adults of the Milieu Intérieur cohort, using quantification of T cell receptor excision circles (TRECs) in peripheral blood T cells as a surrogate marker of thymopoiesis. Age and sex were the only nonheritable factors identified that affect thymic function. TREC amounts decreased with age and were higher in women compared to men. In addition, a genome-wide association study revealed a common variant (rs2204985) within the T cell receptor TCRA-TCRD locus, between the DD2 and DD3 gene segments, which associated with TREC amounts. Strikingly, transplantation of human hematopoietic stem cells with the rs2204985 GG genotype into immunodeficient mice led to thymopoiesis with higher TRECs, increased thymocyte counts, and a higher TCR repertoire diversity. Our population immunology approach revealed a genetic locus that influences thymopoiesis in healthy adults, with potentially broad implications in precision medicine.
Published: 2018

9. A new heterozygous mutation in GP1BA gene responsible for macrothrombocytopenia

Author: Gérard Sébahoun, Xavier Pillois, Véronique Baccini, Hana Raslova, Philippe Rameau, Denis Bernot, Marie-Christine Alessi, Noémie Saut, Dorsaf Ghalloussi, Nutrition, obésité et risque thrombotique (NORT), Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Fibrinolyse et Pathologie Vasculaire, Université de la Méditerranée - Aix-Marseille 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Haut-Lévêque, Université Sciences et Technologies - Bordeaux 1 (UB)-CHU Bordeaux [Bordeaux], Plateforme imagerie et cytométrie (PFIC), Analyse moléculaire, modélisation et imagerie de la maladie cancéreuse (AMMICa), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Hématologie, Hôpital Nord [CHU - APHM], Hématopoïèse normale et pathologique (U1170 Inserm), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Goletto, Marie-Hélène, Aix Marseille Université (AMU)-Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Sciences et Technologies - Bordeaux 1-CHU Bordeaux [Bordeaux], Centre National de la Recherche Scientifique (CNRS)-Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Centre recherche en CardioVasculaire et Nutrition (C2VN)
Subjects: Genetics, [SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, GP1BA gene, Platelet disorder, Heterozygote advantage, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, 030204 cardiovascular system & hematology, Biology, [SDV.GEN.GH] Life Sciences [q-bio]/Genetics/Human genetics, PLATELET DISORDERS, PLATELETS, PLATELET GENETIC DISEASES, 03 medical and health sciences, 0302 clinical medicine, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, Mutation (genetic algorithm), PLATELET MEMBRANE, Platelet, MEGAKARYOCYTOPOIESIS, ComputingMilieux_MISCELLANEOUS, 030215 immunology, Heterozygous mutation, Megakaryocytopoiesis
Abstract: International audience
Published: 2018

10. Southeast asian ovalocytosis: the need for a carefull observation of red cell indices and blood smear

Author: Pierre-Antoine Moulin, Véronique Baccini, Denis Bernot, Vanessa Nivaggioni, Charlotte Grosdidier, Noémie Saut, CHU Marseille, Nutrition, obésité et risque thrombotique (NORT), and Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Adult, Erythrocyte Indices, Male, Pathology, medicine.medical_specialty, [SDV]Life Sciences [q-bio], Cytodiagnosis, Population, Usually asymptomatic, Biology, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Pregnancy, parasitic diseases, medicine, Humans, 030212 general & internal medicine, education, Band 3, education.field_of_study, Incidental Findings, Blood Cells, Hematologic Tests, RED-CELL INDICES, Pregnancy Complications, Hematologic, Elliptocytosis, Hereditary, General Medicine, Middle Aged, medicine.disease, Southeast Asian ovalocytosis, Blood smear, Ovalocytosis, biology.protein, Female, Hemoglobin
Abstract: Southeast asian ovalocytosis (SAO) is characterized by macro-ovalocytes and ovalo-stomatocytes on blood smear. SAO is common in Malaisia and Papua-New-Guinea where upwards to 40 per cent of the population is affected in some coastal region. Inherited in an autosomal dominant way, illness results from deletion of codons 400-408 in SLC4A1 gene which encodes for band 3 erythrocyte membrane protein. This deletion is responsible for an unusual erythrocyte stiffness and oval shape of the cells on blood smear. Heterozygous carriers are usually asymptomatic whereas homozygous are not viable without an intensive antenatal care. Here, we describe 4 patients diagnosed incidentally by cytogram appearance of the Advia® 2120i (Siemens) representing hemoglobin concentration according to red blood mean cellular volume (GR/VCH).
Published: 2017

11. Protein S Heerlen mutation heterozygosity is associated with venous thrombosis risk

Author: Xavier Jouven, Beata Gyorgy, Pierre-Emmanuel Morange, Marie Germain, David M. Smadja, Noémie Saut, Marie-Christine Alessi, Pierre Suchon, Aurélien Delluc, Mona Ibrahim, David-Alexandre Trégouët, Jean-François Deleuze, Laboratoire d'hématologie biologique [Hôpital de la Timone - Hôpital Nord - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Nutrition, obésité et risque thrombotique (NORT), Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), CIC Brest, Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital de la Cavale Blanche, Service d'hématologie biologique [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Innovations thérapeutiques en hémostase (IThEM - U1140), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Université Paris Descartes - Paris 5 (UPD5), Dpt Cardiologie [CHU Georges Pompidou], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Centre National de Génotypage (CNG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Centre d'Etude du Polymorphisme Humain (CEPH), Université Paris Diderot - Paris 7 (UPD7)-Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7)-Fondation Jean Dausset, Aix Marseille Université (AMU)-Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), HAL UPMC, Gestionnaire, Aix Marseille Université ( AMU ) -Assistance Publique - Hôpitaux de Marseille ( APHM ) - Hôpital de la Timone [CHU - APHM] ( TIMONE ), Nutrition, obésité et risque thrombotique ( NORT ), Institut National de la Recherche Agronomique ( INRA ) -Aix Marseille Université ( AMU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition ( ICAN ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -CHU Pitié-Salpêtrière [APHP], Université de Brest ( UBO ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Hôpital de la Cavale Blanche, Service d'hématologie biologique [CHU Hôpital Européen Georges Pompidou], Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Innovations thérapeutiques en hémostase ( IThEM - U1140 ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Descartes - Paris 5 ( UPD5 ), Paris-Centre de Recherche Cardiovasculaire ( PARCC - U970 ), Hôpital Européen Georges Pompidou [APHP] ( HEGP ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Paris Descartes - Faculté de Médecine ( UPD5 Médecine ), Université Paris Descartes - Paris 5 ( UPD5 ), Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Centre National de Génotypage ( CNG ), Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ), Centre d'Etude du Polymorphisme Humain ( CEPH ), Université Paris Diderot - Paris 7 ( UPD7 ) -Institut Universitaire d'Hématologie ( IUH ), and Université Paris Diderot - Paris 7 ( UPD7 ) -Fondation Jean Dausset
Subjects: 0301 basic medicine, medicine.medical_specialty, Mutation, Missense, 030204 cardiovascular system & hematology, medicine.disease_cause, Gastroenterology, Risk Assessment, Protein S, Article, Loss of heterozygosity, 03 medical and health sciences, Plasma, 0302 clinical medicine, Polymorphism (computer science), [ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology, Internal medicine, Genotype, medicine, Humans, Genetic Predisposition to Disease, Venous Thrombosis, Mutation, Multidisciplinary, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, biology, PROTEIN S HEERLEN, business.industry, medicine.disease, Quantitative determination, Surgery, Venous thrombosis, 030104 developmental biology, biology.protein, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: Hereditary Protein S (PS) deficiency is a rare coagulation disorder associated with an increased risk of venous thrombosis (VT). The PS Heerlen (PSH) mutation is a rare S501P mutation that was initially considered to be a neutral polymorphism. However, it has been later shown that PSH has a reduced half-life in vivo which may explain the association of PSH heterozygosity with mildly reduced levels of plasma free PS (FPS). Whether the risk of VT is increased in PSH carriers remains unknown. We analyzed the association of PSH (rs121918472 A/G) with VT in 4,173 VT patients and 5,970 healthy individuals from four independent case-control studies. Quantitative determination of FPS levels was performed in a subsample of 1257 VT patients. In the investigated populations, the AG genotype was associated with an increased VT risk of 6.57 [4.06–10.64] (p = 1.73 10−14). In VT patients in whom PS deficiency was excluded, plasma FPS levels were significantly lower in individuals with PSH when compared to those without [72 + 13 vs 91 + 21 UI/dL; p = 1.86 10−6, mean + SD for PSH carriers (n = 21) or controls (n = 1236) respectively]. We provide strong evidence that the rare PSH variant is associated with VT in unselected individuals.
Published: 2017

12. Genome wide association study for plasma levels of natural anticoagulant inhibitors and protein C anticoagulant pathway: the MARTHA project

Author: Noémie Saut, Mark Lathrop, Choumous Kallel, William Cohen, David-Alexandre Trégouët, Tiphaine Oudot-Mellakh, Pierre-Emmanuel Morange, Marine Germain, and Diana Zelenika
Subjects: Genetics, medicine.medical_specialty, Antithrombin, Locus (genetics), Single-nucleotide polymorphism, Genome-wide association study, Hematology, Biology, Protein S, Endocrinology, Internal medicine, Genetic variation, medicine, biology.protein, SNP, Protein C, medicine.drug
Abstract: Summary Deficiencies of antithrombin (AT), protein C (PC) and protein S (PS) or an impaired PC anticoagulant pathway increase the risk of venous thrombosis (VT). By conducting a genome-wide association study (GWAS) on two independent samples of VT patients totalling 951 subjects typed for 472 173 single nucleotide polymorphisms (SNPs), we observed that common SNPs explain 21% and 27% of the genetic variance of plasma AT and PS levels, even though no SNP reached genome-wide significance. For PC, we showed that two PROCR SNPs, rs867186 (Ser219Gly) and rs6060278, additionally explained c. 20% (P =1 AE19 · 10 )31 ) of the variance of plasma PC levels. We also observed that c. 40% of the remaining genetic variance of PC levels could be due to yet unidentified common SNPs. The PROCR locus was also found to explain c. 8% (P
Published: 2012

13. Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach

Author: Christine Biron-Andreani, Mark Lathrop, Gilles Pernod, Laurence Tiret, Marie-Christine Alessi, Pierre-Emmanuel Morange, Irène Juhan-Vague, Simon Heath, Noémie Saut, Jean-François Schved, Joseph Emmerich, Ludovic Drouet, David-Alexandre Trégouët, Diana Zelenika, and Pilar Galan
Subjects: Risk, Immunology, Locus (genetics), Single-nucleotide polymorphism, Genome-wide association study, Platelet Membrane Glycoproteins, Biology, Lower risk, Polymorphism, Single Nucleotide, Biochemistry, ABO Blood-Group System, Cytochrome P-450 Enzyme System, ABO blood group system, Genotype, Humans, Genetic Predisposition to Disease, Cytochrome P450 Family 4, cardiovascular diseases, Allele, Alleles, Genetics, Case-control study, Factor V, Venous Thromboembolism, Cell Biology, Hematology, equipment and supplies, Case-Control Studies, Genome-Wide Association Study
Abstract: Venous thromboembolism (VTE) is a complex disease that has a major genetic component of risk. To identify genetic factors that may modify the risk of VTE, we conducted a genome-wide association study by analyzing approximately 317 000 single nucleotide polymorphisms (SNPs) in 453 VTE cases and 1327 controls. Only 3 SNPs located in the FV and ABO blood group genes were found associated with VTE at a genome-wide significant level of 1.7 × 10−7. Detailed analysis of these SNPs in additional cohorts of more than 1700 cases and 1400 controls revealed that the association observed at the FV locus was the result of the increased risk mediated by the FV Leiden mutation, whereas O and A2 blood groups were found to be at lower risk for VTE. Apart from the FV and ABO loci, no other locus was found strongly associated with VTE. However, using this large cohort of subjects, we were able to replicate the mild effects of 2 nonsynonymous SNPs, rs1613662 in GP6 and rs13146272 in CYP4V2, recently suspected to be associated with VTE.
Published: 2009

14. Polymorphisms of the tumor necrosis factor-alpha (TNF) and the TNF-alpha converting enzyme (TACE/ADAM17) genes in relation to cardiovascular mortality: the AtheroGene study

Author: Stefan Blankenberg, Noémie Saut, Christoph Bickel, Hans-Jürgen Rupprecht, David-Alexandre Trégouët, Tiphaine Godefroy, K.J. Lackner, Sandrine Barbaux, Irène Juhan-Vague, Franck Peiretti, Pierre Morange, Gilles Nalbone, Odette Poirier, and Laurence Tiret
Subjects: Male, medicine.medical_specialty, Genotype, medicine.medical_treatment, Single-nucleotide polymorphism, Inflammation, Coronary Artery Disease, ADAM17 Protein, Biology, Polymorphism, Single Nucleotide, Coronary artery disease, Gene Frequency, Internal medicine, Drug Discovery, medicine, Humans, Receptors, Tumor Necrosis Factor, Type II, Genetic Predisposition to Disease, Prospective cohort study, Alleles, Genetics (clinical), Aged, Tumor Necrosis Factor-alpha, Odds ratio, Middle Aged, medicine.disease, Molecular medicine, Survival Rate, ADAM Proteins, Phenotype, Endocrinology, Cytokine, Haplotypes, Receptors, Tumor Necrosis Factor, Type I, Molecular Medicine, Female, Tumor necrosis factor alpha, medicine.symptom
Abstract: Tumor necrosis factor (TNF) is a major cytokine involved in inflammatory reaction and a mortality predictor in patients with coronary artery disease (CAD). Plasma levels of soluble TNF (sTNF) depend on the rate of its synthesis but also on its shedding from cell surface, a mechanism mainly regulated by the TNF alpha converting enzyme (TACE or ADAM17). We investigated the relationship between ADAM17 and TNF polymorphisms, circulating levels of shed ADAM17 substrates (sTNF, sTNFR1 and sTNFR2), and cardiovascular risk in a prospective cohort of CAD patients. Five tag single-nucleotide polymorphisms (SNPs) of the ADAM17 gene as well as four previously described TNF SNPs were genotyped in the Atherogene Study composed of 1,400 CAD patients among which 136 died from a cardiovascular (CV) cause. sTNF, sTNFR1, and sTNFR2 concentrations were all significantly elevated in patients with future CV death, independently of other clinical/biological variables. While none of the studied TNF SNPs was associated with sTNF, sTNFR1, nor sTNFR2 levels, the ADAM17 -154A allele was found associated with a 14% increase of sTNF levels as compared to the -154C allele (p = 0.0066). Moreover, individuals carrying the 747Leu allele displayed a borderline increased risk of future cardiovascular death [odds ratio, 2.06 (1.05-4.04), p = 0.03]. These results suggest a role of ADAM17 in the regulation of sTNF plasma levels and identifies ADAM17 gene as a candidate for CAD. Tumor necrosis factor (TNF) is a major cytokine involved in inflammatory reaction and a mortality predictor in patients with coronary artery disease (CAD). We have studied the association of ADAM17 and TNF polymorphisms with circulating levels of shed ADAM17 substrates (sTNF, sTNFR1 and sTNFR2) and with cardiovascular risk in a large population of individuals with CAD (Atherogene Study, n = 1,400). Two newly identified polymorphisms, obtained by a systematic sequencing of the ADAM17 gene, C-154A and Ser747leu, slightly influence respectively sTNF plasma levels and the risk of cardiovascular death.
Published: 2008

15. Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism

Author: Christophe Tzourio, Lasse Folkersen, Marieke C H De Visser, Sara Lindström, Ramin Monajemi, Noémie Saut, David M. Smadja, Antonio Fabio Di Narzo, Jean-François Dartigues, Paul M. Ridker, Marine Germain, Mete Civelek, Nicholas L. Smith, François Cambien, Ares Rocanin-Arjo, Christopher Kabrhel, Alison H. Goodall, Aaron R. Folsom, Pieter H. Reitsma, Saonli Basu, Eline Slagboom, Lu-Chen Weng, Kent D. Taylor, Hugoline G. de Haan, Jeanine Houwing-Duitermaat, Peter Kraft, Panos Deloukas, Christopher P. Nelson, Claudine Berr, Lynda M. Rose, Ke Hao, Bruce M. Psaty, Nilesh J. Samani, Jennifer A. Brody, Pierre Suchon, Philippe Amouyel, Jean-François Deleuze, Kerri L. Wiggins, Grégoire Le Gal, Daniel I. Chasman, John A. Heit, Dylan Aïssi, Astrid van Hylckama Vlieg, Pierre-Emmanuel Morange, Mariza de Andrade, Weihong Tang, Frits R. Rosendaal, David-Alexandre Trégouët, Per Eriksson, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Brigham and Women's Hospital [Boston], Department of Thrombosis and Haemostasis, Leiden University Medical Center (LUMC), Universiteit Leiden-Universiteit Leiden, University of Minnesota [Twin Cities] (UMN), University of Minnesota System, Program in Genetic Epidemiology and Statistical Genetics (PGESG - BOSTON), Harvard School of Public Health, Mayo Clinic (MC), Division of Biomedical Statistics and Informatics, Mayo Clinic, Einthoven Laboratory for Experimental Vascular Medicine (ELEVM - LEIDEN), Department of Epidemiology, University of Washington [Seattle], Nutrition, obésité et risque thrombotique (NORT), Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire d'hématologie, Assistance Publique - Hôpitaux de Marseille (APHM), Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Université Paris Descartes - Paris 5 (UPD5), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Innovations thérapeutiques en hémostase (IThEM - U1140), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Investigation Clinique (CIC - Brest), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'angiologie et d'hémostase (MR), Hôpital Universitaire de Genève = University Hospitals of Geneva (HUG), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai [New York] (MSSM), NIHR Leicester Cardiovascular Biomedical Research Unit, University of Leicester, Department of Cardiovascular Sciences [Leicester], Department of PharmacoGenetics (DPG - COPENHAGEN), NOVO NORDISK PARK, Department of Medical Statistics and Bioinformatics, Harvard Medical School [Boston] (HMS), Section Molecular Epidemiology, Leiden University Medical Center (LUMC), Division of epidemiology, Dalla Lana School of Public Health, University of Toronto, Centre National de Génotypage (CNG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Princess Al Jawhara Center of Excellence in the Research of Hereditary Disorders, King Abdulaziz University, William Harvey Research Institute, Barts and the London Medical School, Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Los Angeles Biomedical Research Institute and Department of Pediatrics (LA Biomed Res Institute), Harbor UCLA Medical Center [Torrance, Ca.], Department of medicine [Stockholm], Karolinska Institutet [Stockholm]-Karolinska University Hospital [Stockholm], Atherosclerosis Research Unit, Karolinska Institutet [Stockholm]-Department of Medicine Solna-Cardiovascular Genetics Group, Group Health Research Institute, Group Health Cooperative, Université de Lille, Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP), Leicester NIHR Biomedical Research Unit in Cardiovascular Disease, Division of Biostatistics (Biostat - MINNEAPOLIS), University of Minnesota System-University of Minnesota System, Department of Emergency Medicine, Massachusetts General Hospital [Boston], Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, Seattle Epidemiologic Research and Information Center of the Department of Veterans Affairs Office of Research and Development, Fibrinolyse et Pathologie Vasculaire, Université de la Méditerranée - Aix-Marseille 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Universitaire de Genève, Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO)-Université de Brest (UBO), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition ( ICAN ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -CHU Pitié-Salpêtrière [APHP], Division of Epidemiology & Community Health, Univ of Minnesota, Minneapolis , MN, Program in Genetic Epidemiology and Statistical Genetics ( PGESG - BOSTON ), Mayo Clinic ( MC ), Einthoven Laboratory for Experimental Vascular Medicine ( ELEVM - LEIDEN ), Nutrition, obésité et risque thrombotique ( NORT ), Institut National de la Recherche Agronomique ( INRA ) -Aix Marseille Université ( AMU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance Publique - Hôpitaux de Marseille ( APHM ), Université Paris Descartes - Faculté de Médecine ( UPD5 Médecine ), Université Paris Descartes - Paris 5 ( UPD5 ), Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Innovations thérapeutiques en hémostase ( IThEM - U1140 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre d'Investigation Clinique ( CIC - Brest ), Université de Brest ( UBO ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service d'angiologie et d'hémostase ( MR ), Groupe d'Etude de la Thrombose de Bretagne Occidentale ( GETBO ), Université de Brest ( UBO ), Mount Sinai School of Medicine, Department of PharmacoGenetics ( DPG - COPENHAGEN ), Division of Preventive Medicine, Department of Medicine, Brigham and Women ’ s Hospital, Harvard Medical School, Boston, MA, USA, Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, Washington, USA, Centre National de Génotypage ( CNG ), Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ), Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Neuropsychiatrie : recherche épidémiologique et clinique, Université Montpellier 1 ( UM1 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Montpellier ( UM ), Los Angeles Biomedical Research Institute and Department of Pediatrics ( LA Biomed Res Institute ), Harbor UCLA Medical Center 1000 W Carson Street, Réseau International des Instituts Pasteur ( RIIP ) -Réseau International des Instituts Pasteur ( RIIP ), Division of Biostatistics ( Biostat - MINNEAPOLIS ), University of Minnesota [Minneapolis], Massachusetts General Hospital, Harvard Medical School, Université de la Méditerranée - Aix-Marseille 2-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP], University of Minnesota [Twin Cities], Aix Marseille Université (AMU)-Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), and Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)
Subjects: Genotype, Tetraspanins, [SDV]Life Sciences [q-bio], Genome-wide association study, Single-nucleotide polymorphism, Disease, 030204 cardiovascular system & hematology, Lung injury, Biology, Bioinformatics, Article, 03 medical and health sciences, 0302 clinical medicine, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology, Genetics, Odds Ratio, SNP, Humans, Genetics(clinical), Genetic Predisposition to Disease, cardiovascular diseases, Genetics (clinical), 030304 developmental biology, Genetic association, 0303 health sciences, Membrane Glycoproteins, [ SDV ] Life Sciences [q-bio], Membrane Transport Proteins, Odds ratio, Venous Thromboembolism, [ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, equipment and supplies, 3. Good health, Meta-analysis, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Genome-Wide Association Study
Abstract: International audience; Venous thromboembolism (VTE), the third leading cause of cardiovascular mortality, is a complex thrombotic disorder with environmental and genetic determinants. Although several genetic variants have been found associated with VTE, they explain a minor proportion of VTE risk in cases. We undertook a meta-analysis of genome-wide association studies (GWASs) to identify additional VTE susceptibility genes. Twelve GWASs totaling 7,507 VTE case subjects and 52,632 control subjects formed our discovery stage where 6,751,884 SNPs were tested for association with VTE. Nine loci reached the genome-wide significance level of 5 × 10(-8) including six already known to associate with VTE (ABO, F2, F5, F11, FGG, and PROCR) and three unsuspected loci. SNPs mapping to these latter were selected for replication in three independent case-control studies totaling 3,009 VTE-affected individuals and 2,586 control subjects. This strategy led to the identification and replication of two VTE-associated loci, TSPAN15 and SLC44A2, with lead risk alleles associated with odds ratio for disease of 1.31 (p = 1.67 × 10(-16)) and 1.21 (p = 2.75 × 10(-15)), respectively. The lead SNP at the TSPAN15 locus is the intronic rs78707713 and the lead SLC44A2 SNP is the non-synonymous rs2288904 previously shown to associate with transfusion-related acute lung injury. We further showed that these two variants did not associate with known hemostatic plasma markers. TSPAN15 and SLC44A2 do not belong to conventional pathways for thrombosis and have not been associated to other cardiovascular diseases nor related quantitative biomarkers. Our findings uncovered unexpected actors of VTE etiology and pave the way for novel mechanistic concepts of VTE pathophysiology.
Published: 2015

16. Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact

Author: Pierre-Emmanuel Morange, Jérôme Beltran, Mariana Grosley, Marie-Christine Alessi, Irène Juhan-Vague, Noémie Saut, David-Alexandre Trégouët, and Corinne Frere
Subjects: Male, Gene isoform, Carboxypeptidase B2, Genotype, medicine.medical_treatment, Myocardial Infarction, Enzyme-Linked Immunosorbent Assay, Biology, Sensitivity and Specificity, Gene Frequency, Risk Factors, Fibrinolysis, medicine, Humans, Protein Isoforms, Genetic Predisposition to Disease, Allele, Allele frequency, Gene, Alleles, Polymorphism, Genetic, Haplotype, Reproducibility of Results, Hematology, Molecular biology, Genetic Techniques, Haplotypes, Case-Control Studies, Gene polymorphism, Artifacts
Abstract: SummaryReports have reappraised the genotype-dependent variation of Thrombin Activatable Fibrinolysis Inhibitor (TAFI), demonstrating that, in some enzyme-linked immunosorbent assays (ELISA), decreased antibody reactivity towards the TAFI 325 Ile isoform led to erroneous TAFI levels. Assays free of this artefact are required to evaluate the contribution of theTAFI gene polymorphisms toTAFI level variability.TAFI levels were measured in 209 individuals with both immunological and functional assays. Each assay was characterized, in particular for its reactivity towards the 325 Thr and Ile isoforms. Two ELISAs were found to have a lower reactivity towards the Ile isoform, leading to an overesti-mate of the magnitude of variation between two different genotypes. In contrast, one ELISA, as well as functional assays, was found to be free of genotype-dependent artefact constituting a reliable method to detect true quantitative variations of TAFI levels. Using these reliable methods, univariate and haplotype analyses revealed that TAFI gene polymorphisms explain 25% of TAFI level variability. This effect seems to be the consequence of the joint independent action of two polymorphisms, one in the 5’ (G-1102T) and the other in the 3’ region (T+1583A) of the TAFI gene.
Published: 2005

17. Biological and genetic factors influencing plasma factor VIII levels in a healthy family population: results from the Stanislas cohort

Author: Pierre Morange, L. Pellegrina, Marie-Christine Alessi, Corinne Frere, Sophie Visvikis, Noémie Saut, Laurence Tiret, Irène Juhan-Vague, and David-Alexandre Trégouët
Subjects: congenital, hereditary, and neonatal diseases and abnormalities, medicine.medical_specialty, Genotype, animal diseases, Population, Biology, ABO Blood-Group System, Cohort Studies, Von Willebrand factor, Polymorphism (computer science), hemic and lymphatic diseases, ABO blood group system, Internal medicine, Blood plasma, medicine, Humans, Genetic variability, Allele, education, Blood Coagulation, Receptors, Lipoprotein, education.field_of_study, Binding Sites, Factor VIII, Polymorphism, Genetic, Lipoprotein receptor-related protein, Hematology, Pedigree, Endocrinology, Immunology, biology.protein
Abstract: The mechanisms underlying the variability of factor VIII (FVIII) levels are still poorly understood. The only receptor of FVIII identified so far is the lipoprotein receptor-related protein (LRP), which is thought to be involved in FVIII degradation. We aimed to characterize biological and genetic factors related to FVIII variability, focusing on coding polymorphisms of the LRP gene and polymorphisms potentially detected by molecular screening of the LRP-binding domains of the FVIII gene. Plasma FVIII coagulant activity (FVIII:C) and von Willebrand factor (VWF:Ag) antigen levels were measured in a sample of 100 healthy nuclear families (200 parents and 224 offspring). The ABO blood group and the three coding polymorphisms of the LRP gene (A217V, D2080N and C766T) were genotyped. Lipids and anthropometric factors poorly contributed to the variability of FVIII:C (
Published: 2005

18. A meta-analysis of genome-wide association studies identifies ORM1 as a novel gene controlling thrombin generation potential

Author: David-Alexandre Trégouët, Anne-Marie Dupuy, Noémie Saut, Marine Germain, Martine Alhenc-Gelas, Corinne Frere, Luc Letenneur, Philipp S. Wild, Alison H. Goodall, Ares Rocanin-Arjo, Philippe Amouyel, Pierre-Emmanuel Morange, Marie-Christine Alessi, Laure Carcaillon, Marion Bertrand, William Cohen, François Cambien, Tanja Zeller, and Pierre-Yves Scarabin
Subjects: Genetics, Adult, Male, Immunology, Thrombin, Genome-wide association study, Cell Biology, Hematology, Orosomucoid, Biology, Middle Aged, Biochemistry, Thrombin generation, Polymorphism, Single Nucleotide, Novel gene, Meta-analysis, medicine, Humans, Female, Blood Coagulation Tests, Gene, circulatory and respiratory physiology, medicine.drug, Genome-Wide Association Study
Abstract: Thrombin, the major enzyme of the hemostatic system, is involved in biological processes associated with several human diseases. The capacity of a given individual to generate thrombin, called the thrombin generation potential (TGP), can be robustly measured in plasma and was shown to associate with thrombotic disorders. To investigate the genetic architecture underlying the interindividual TGP variability, we conducted a genome-wide association study in 2 discovery samples (N = 1967) phenotyped for 3 TGP biomarkers, the endogenous thrombin potential, the peak height, and the lag time, and replicated the main findings in 2 independent studies (N = 1254). We identified the ORM1 gene, coding for orosomucoid, as a novel locus associated with lag time variability, reflecting the initiation process of thrombin generation with a combined P value of P = 7.1 × 10(-15) for the lead single nucleotide polymorphism (SNP) (rs150611042). This SNP was also observed to associate with ORM1 expression in monocytes (P = 8.7 × 10(-10)) and macrophages (P = 3.2 × 10(-3)). In vitro functional experiments further demonstrated that supplementing normal plasma with increasing orosomucoid concentrations was associated with impaired thrombin generation. These results pave the way for novel mechanistic pathways and therapeutic perspectives in the etiology of thrombin-related disorders.
Published: 2013

19. The human Y chromosome genes BPY2, CDY1 and DAZ are not essential for sustained fertility

Author: Noémie Saut, Nicolas Lévy, Michael J. Mitchell, P. Terriou, and A. Navarro
Subjects: Adult, Male, Infertility, Embryology, DNA, Complementary, Molecular Sequence Data, BPY2, Biology, Y chromosome, Y Chromosome, Genetics, medicine, Humans, Gene family, Allele, Molecular Biology, Gene, Southern blot, Azoospermia, Base Sequence, Nuclear Proteins, Proteins, RNA-Binding Proteins, Obstetrics and Gynecology, Deleted in Azoospermia 1 Protein, Oligospermia, Cell Biology, medicine.disease, Pedigree, Reproductive Medicine, Female, Chromosome Deletion, Developmental Biology
Abstract: Deletions of the AZFc interval of the human Y chromosome are found in >5% of male patients with idiopathic infertility and are associated with a severely reduced sperm count. The most common deletion type is large (>1 Mb) and removes members of the Y-borne testis-specific gene families of BPY2, CDY1, DAZ, PRY, RBMY2 and TTY2, which are candidate AZF genes. Four exceptional individuals who have transmitted a large AZFc deletion naturally to their infertile sons have, however, been described. In three cases, transmission was to an only son, but in the fourth case a Y chromosome, shown to be deleted for all copies of DAZ, was transmitted from a father to his four infertile sons. Here we present a second family of this latter type and demonstrate that an AZFc-deleted Y chromosome lacking not only DAZ, but also BPY2 and CDY1, has been transmitted from a father to his three infertile sons. Polymerase chain reaction (PCR) and Southern blot analyses revealed no difference in the size of the AZFc deletion in the father and his sons. We propose that the father carries rare alleles of autosomal or X-linked loci which suppress the infertility that is frequently associated with the absence of AZFc.
Published: 2000

20. Dendritic Cells Permit Identification of Genes Encoding MHC Class II–Restricted Epitopes of Transplantation Antigens

Author: Stipo Jurcevic, Michael J. Mitchell, P. Ellis, Elizabeth Simpson, Eddie A. James, Diane Scott, Caroline Addey, and Noémie Saut
Subjects: Eukaryotic Initiation Factor-2, Genes, MHC Class II, H-Y Antigen, Molecular Sequence Data, Immunology, Epitopes, T-Lymphocyte, Mice, Transgenic, Major histocompatibility complex, Epitope, DEAD-box RNA Helicases, Minor Histocompatibility Antigens, Mice, Antigen, Histocompatibility Antigens, Animals, Immunology and Allergy, Amino Acid Sequence, Histone Demethylases, MHC class II, COS cells, biology, H-2 Antigens, Nuclear Proteins, Proteins, Dendritic Cells, MHC restriction, Virology, Molecular biology, Immunity, Innate, Histocompatibility, Mice, Inbred C57BL, Infectious Diseases, Gene Expression Regulation, Mice, Inbred CBA, biology.protein, Female, Peptides, CD8
Abstract: Minor or histocompatibility (H) antigens are recognized by CD4 + and CD8 + T lymphocytes as short polymorphic peptides associated with MHC molecules. They are the targets of graft versus host and graft versus leukemia responses following bone marrow transplantation between HLA-identical siblings. Several genes encoding class I–restricted minor H epitopes have been identified, but approaches used for these have proved difficult to adapt for cloning class II–restricted minor H genes. We have combined the unique antigen-presenting properties of dendritic cells and high levels of episomal expression following transfection of COS cells to identify a Y chromosome gene encoding two HY peptide epitopes, HYA b and HYE k .
Published: 2000

21. ABO blood group and von Willebrand factor levels partially explained the incomplete penetrance of congenital thrombophilia

Author: Marie-Christine Alessi, Noémie Saut, David-Alexandre Trégouët, William Cohen, Géraldine Lavigne, Sophie Bouvet, Christel Castelli, Pierre-Emmanuel Morange, Dominique Brunet, Marie-Françoise Aillaud, and M. C. Barthet
Subjects: Adult, Male, Risk, medicine.medical_specialty, Thrombophilia, Gastroenterology, ABO Blood-Group System, Von Willebrand factor, Internal medicine, ABO blood group system, von Willebrand Factor, medicine, Coagulopathy, Factor V Leiden, Humans, Aged, Venous Thrombosis, Factor VIII, biology, business.industry, Antithrombin, Middle Aged, medicine.disease, Venous thrombosis, Immunology, biology.protein, Female, Cardiology and Cardiovascular Medicine, business, Protein C, medicine.drug
Abstract: Objective— We aimed to study the association among ABO blood group, von Willebrand factor, factor VIII plasma levels, and the risk of venous thrombosis (VT) in a cohort of 1774 relatives from 500 families with inherited thrombophilia. Methods and Results— One hundred sixty-one of the 1774 relatives had a VT. Different risk groups were formed: no, low-(factor V Leiden or F2G20210A heterozygous carriers), and high-risk thrombophilia (antithrombin, protein C, protein S, factor V Leiden, or F2G20210A homozygous carriers and combined defects). Compared with group O, AB blood group was associated with increased risk of VT: hazard ratio (HR)=3.8 (2.0–7.2). The effect of blood group A and B was milder (HR=1.6 [1.1–2.5] and 1.8 [1.0–3.3], respectively). An increased risk of VT was observed with increasing levels of von Willebrand factor and factor VIII plasma levels (HR=2.96 [1.92–4.56] and HR=2.60 [1.92–4.56] for third versus first tertile of von Willebrand factor and factor VIII plasma levels, respectively). In multivariate analysis, AB group (HR=2.3 [1.1–4.8]), high-risk thrombophilia (HR=2.8 [1.6–4.6]), and high von Willebrand factor levels (HR=2.3 [1.3–4.0]) were significantly associated with increased risk of VT. The risk of VT in individuals with high-risk thrombophilia and AB group was 14.4× higher than in those without thrombophilia and O group (5.0–41.4). Conclusion— ABO blood group modifies the risk of VT in families with hereditary thrombophilia. Phenotyping of the ABO blood group should be performed to better assess the risk of VT in asymptomatic individuals from thrombophilic families.
Published: 2012

22. Association of soluble endothelial protein C receptor plasma levels and PROCR rs867186 with cardiovascular risk factors and cardiovascular events in coronary artery disease patients: The AtheroGene Study

Author: Thomas Münzel, Choumous Kallel, Stefan Blankenberg, Noémie Saut, David-Alexandre Trégouët, Renate B. Schnabel, William Cohen, Pierre-Emmanuel Morange, Hans J. Rupprecht, Christoph Bickel, BMC, Ed., Nutrition, obésité et risque thrombotique (NORT), Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of General and Interventional Cardiology, University Heart Center Hamburg, Department of Medicine II, Johannes Gutenberg - Universität Mainz = Johannes Gutenberg University (JGU), Federal Armed Forces Central Hospital Koblenz, Génomique cardiovasculaire, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), This work was supported by a grant of the Programme National de Recherche sur les Maladies Cardiovasculaires 2006 (A06034AS), by the 'Stiftung Rheinland-Pfalz für Innovation', Ministry for Science and Education (AZ 15202-386261/545), Mainz, by the MAIFOR grant 2001 of the Johannes Gutenberg-University Mainz, Germany and by a grant from the Fondation de France (no. 2002004994)., Aix Marseille Université (AMU)-Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Johannes Gutenberg - Universität Mainz (JGU)
Subjects: Male, lcsh:Internal medicine, medicine.medical_specialty, Acute coronary syndrome, lcsh:QH426-470, Cardiovascular risk factors, Receptors, Cell Surface, [SDV.GEN] Life Sciences [q-bio]/Genetics, 030204 cardiovascular system & hematology, Biology, [SDV.GEN.GH] Life Sciences [q-bio]/Genetics/Human genetics, Polymorphism, Single Nucleotide, Coronary artery disease, Endothelial protein C receptor, Angina Pectoris, 03 medical and health sciences, 0302 clinical medicine, Antigens, CD, Risk Factors, Internal medicine, Genetics, medicine, Humans, Genetics(clinical), Acute Coronary Syndrome, lcsh:RC31-1245, Gene, Genetics (clinical), 030304 developmental biology, 0303 health sciences, [SDV.GEN]Life Sciences [q-bio]/Genetics, medicine.disease, lcsh:Genetics, Coagulation, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, Cardiovascular Diseases, Immunology, Cardiology, Biomarker (medicine), Female, Biomarkers, Protein C, Research Article, medicine.drug, Haemostasis
Abstract: Background Blood coagulation is an essential determinant of coronary artery disease (CAD). Soluble Endothelial Protein C Receptor (sEPCR) may be a biomarker of a hypercoagulable state. We prospectively investigated the relationship between plasma sEPCR levels and the risk of cardiovascular events (CVE). Methods We measured baseline sEPCR levels in 1673 individuals with CAD (521 with acute coronary syndrome [ACS] and 1152 with stable angina pectoris [SAP]) from the AtheroGene cohort. During a median follow up of 3.7 years, 136 individuals had a CVE. In addition, 891 of these CAD patients were genotyped for the PROCR rs867186 (Ser219Gly) variant. Results At baseline, sEPCR levels were similar in individuals with ACS and SAP (median: 111 vs. 115 ng/mL respectively; p=0.20). Increased sEPCR levels were found to be associated with several cardiovascular risk factors including gender (p=0.006), soluble Tissue Factor levels (p=0.0001), diabetes (p=0.0005), and factors reflecting impaired renal function such as creatinine and cystatin C (p-200) but did not associate with CVE risk. Conclusion Our findings show that in patients with CAD, circulating sEPCR levels are related to classical cardiovascular risk factors and renal impairment but are not related to long-term incidence of CVE.
Published: 2012

23. Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus. Results from the D.E.S.I.R. prospective cohort

Author: Bénédicte Fontaine-Bisson, Pierre-Emmanuel Morange, Noémie Saut, Marie-Christine Alessi, Beverley Balkau, Viviane Nicaud, David-Alexandre Trégouët, Irène Juhan-Vague, Céline Lange, Frédéric Fumeron, Ilse Scroyen, Olivier Lantieri, and Michel Marre
Subjects: 0301 basic medicine, Adult, Male, Risk, medicine.medical_specialty, Time Factors, Genotype, Type 2 diabetes, 030204 cardiovascular system & hematology, Polymorphism, Single Nucleotide, Cohort Studies, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Insulin resistance, Internal medicine, Plasminogen Activator Inhibitor 1, medicine, Humans, Vitronectin, Prospective cohort study, Aged, Metabolic Syndrome, biology, business.industry, Type 2 Diabetes Mellitus, Hematology, Middle Aged, medicine.disease, Prognosis, 030104 developmental biology, Endocrinology, chemistry, Diabetes Mellitus, Type 2, Plasminogen activator inhibitor-1, Case-Control Studies, biology.protein, Female, Metabolic syndrome, business, Plasminogen activator, Biomarkers
Abstract: SummaryIt was the objective of this study to investigate the relation between vitronectin and plasminogen activator inhibitor (PAI)-1 plasma levels with nine-year incidences of the metabolic syndrome (MetS) and of type 2 diabetes mellitus (T2DM). Baseline plasma concentrations of vitronectin and PAI-1 were measured in 627 healthy participants from the prospective D.E.S.I.R. cohort who subsequently developed MetS (n=487) and T2DM (n=182) over a nine-year follow-up (42 presented both) and who were matched with two healthy control subjects each by use of a nested case-control design. Parameters composing the MetS explained about 20% of plasma vitronectin levels. An increase of one standard deviation of vitronectin was associated with increased risks of both the MetS (odds ratio [OR] = 1.21 [1.07 – 1.37], p = 0.003) and T2DM (OR = 1.24 [1.01 – 1.53], p = 0.045). Corresponding ORs for PAI-1 levels were 1.46 [1.27 – 1.68] (p < 10−4) and 1.40 [1.14 – 1.72] (p = 0.0012). However, the effects of vitronectin and PAI-1 levels on outcomes were not independent. The vitronectin–MetS association was restricted to individuals with low to modest PAI-1 levels (OR = 1.33 [1.14 – 1.54], p = 0.0003) while no association was observed in individuals with high PAI-1 levels (OR = 0.87 [0.68 – 1.10], p = 0.24), the test for interaction being highly significant (p = 0.0009). In conclusion, baseline plasma vitronectin is a marker of incident MetS at nine years. Its predictive ability for MetS and T2DM should not be assessed independently of PAI-1 levels.
Published: 2011

24. Complete deletion of the AZFb interval from the Y chromosome in an oligozoospermic man

Author: Marie-Roberte Guichaoua, Michael J. Mitchell, Rachel Levy, Guy Longepied, Catherine Metzler-Guillemain, Noémie Saut, I. Aknin-Seifer, and Anne-Marie Frances
Subjects: Adult, Male, Molecular Sequence Data, Locus (genetics), Biology, Y chromosome, Male infertility, Meiosis, Spermatocytes, medicine, Humans, Spermatogenesis, Aged, Azoospermia, Sequence Deletion, Genetics, Chromosomes, Human, Y, Base Sequence, Rehabilitation, Synapsis, Obstetrics and Gynecology, Oligospermia, medicine.disease, Synaptonemal complex, Chromosome Pairing, medicine.anatomical_structure, Reproductive Medicine, Germ cell
Abstract: background: Deletion of the entire AZFb interval from the Y chromosome is strictly associated with azoospermia arising from maturation arrest during meiosis. Here, we describe the exceptional case of an oligozoospermic man, 13-1217, with an AZFb + c (P5/distal-P1) deletion. Through the characterization of this patient, and two AZFb (P5/proximal-P1) patients with maturation arrest, we have explored three possible explanations for his exceptionally progressive spermatogenesis. methods and results: We have determined the precise breakpoints of the deletion in 13-1217, and shown that 13-1217 is deleted for more AZFb material than one of the AZFb-deleted men (13-5349). Immunocytochemical analysis of spermatocytes with an antibody against a synaptonemal complex component indicates synapsis to be largely unaffected in 13-1217, in contrast to 13-5349 where extended asynapsis is frequent. Using PCR-based analyses of RNA and DNA from the same testicular biopsy, we show that 13-1217 expresses post-meiotic germ cell markers in the absence of genomic DNA and transcripts from the AZFb and AZFc intervals. We have determined the Y chromosome haplogroup of 13-1217 to be HgL-M185. conclusions: Our results indicate that the post-meiotic spermatogenesis in 13-1217 is not a consequence of mosaicism or retention of a key AZFb gene. On the contrary, since the Hg-L Y chromosome carried by 13-1217 is uncommon in Western Europe, a Y-linked modifier locus remains a possible explanation for the oligozoospermia observed in patient 13-1217. Further cases must now be studied to understand how germ cells complete spermatogenesis in the absence of the AZFb interval.
Published: 2010

25. A follow-up study of a genome-wide association scan identifies a susceptibility locus for venous thrombosis on chromosome 6p24.1

Author: Marie-Christine Alessi, Mark Lathrop, Simon Heath, Diana Zelenika, Jessy Brocheton, Jean-François Schved, Marine Germain, Pilar Galan, Ewa Ninio, Stefan Blankenberg, Thomas Münzel, Joseph Emmerich, Irene D. Bezemer, Christine Biron-Andreani, François Cambien, Aurélien Delluc, Noémie Saut, Tanja Zeller, David-Alexandre Trégouët, Ludovic Drouet, Frits R. Rosendaal, Laurence Tiret, Pierre-Emmanuel Morange, Viviane Nicaud, Hervé Durand, Stefan-Martin Brand-Herrmann, Gwenaelle Burgos, Lance A. Bare, Gilles Pernod, Nutrition, obésité et risque thrombotique (NORT), Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Génomique cardiovasculaire, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Génétique épidémiologique et moléculaire des pathologies cardiovasculaires, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR14-Institut National de la Santé et de la Recherche Médicale (INSERM), Département d'hématologie biologique[Montpellier], Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-CHU Saint-Eloi, Techniques pour l'Evaluation et la Modélisation des Actions de la Santé (TIMC-IMAG-ThEMAS), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF), Unité de Recherche en Epidémiologie Nutritionnelle (UREN), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Sorbonne Paris Cité (USPC)-Université Paris 13 (UP13)-Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Institut National de la Recherche Agronomique (INRA), Service de Biochimie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-IFR6, Centre National de Génotypage (CNG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Département de Médecine Interne et Pneumologie [Brest] (DMIP - Brest), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), Department of Medicine II, Johannes Gutenberg - Universität Mainz (JGU), Hôpital de la Timone [CHU - APHM] (TIMONE), Institut de Génomique d'Evry (IG), Institut de Biologie François JACOB (JACOB), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Department of General and Interventional Cardiology, University Heart Center Hamburg, Risque Thrombotique et Mecanismes de l'Hemostase (U765), Institut des sciences du Médicament -Toxicologie - Chimie - Environnement (IFR71), Institut National de la Santé et de la Recherche Médicale (INSERM)-Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Paris Descartes - Paris 5 (UPD5)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Université Paris 13 (UP13)-Institut National de la Recherche Agronomique (INRA)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Johannes Gutenberg - Universität Mainz = Johannes Gutenberg University (JGU), Université Paris-Saclay-Institut de Biologie François JACOB (JACOB), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Risque Thrombotique et Mécanismes de l'Hémostase (U765), Institut de Recherche pour le Développement (IRD)-Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Nutrition, obésité et risque thrombotique ( NORT ), Institut National de la Recherche Agronomique ( INRA ) -Aix Marseille Université ( AMU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -IFR14-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Montpellier 1 ( UM1 ) -Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ) -CHU Saint-Eloi, ThEMAS, Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications [Grenoble] ( TIMC-IMAG ), Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut polytechnique de Grenoble - Grenoble Institute of Technology ( Grenoble INP ) -IMAG-Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ) -Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut polytechnique de Grenoble - Grenoble Institute of Technology ( Grenoble INP ) -IMAG-Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ), Unité de Recherche en Epidémiologie Nutritionnelle ( UREN ), Université Paris 13 ( UP13 ) -Institut National de la Recherche Agronomique ( INRA ) -Conservatoire National des Arts et Métiers [CNAM] ( CNAM ) -Université Sorbonne Paris Cité ( USPC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Lariboisière-IFR6, Centre National de Génotypage ( CNG ), Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ), Département de Médecine Interne et Pneumologie [Brest] ( DMIP - Brest ), Centre Hospitalier Régional Universitaire de Brest ( CHRU Brest ), Groupe d'Etude de la Thrombose de Bretagne Occidentale ( GETBO ), Université de Brest ( UBO ), Johannes Gutenberg-University Mainz, Hôpital de la Timone [CHU - APHM] ( TIMONE ), Institut de Génomique d'Evry ( IG ), Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université Paris-Saclay, Risque Thrombotique et Mecanismes de l'Hemostase ( U765 ), Institut des sciences du Médicament -Toxicologie - Chimie - Environnement ( IFR71 ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Ecole Nationale Supérieure de Chimie de Paris- Chimie ParisTech-PSL ( ENSCP ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut de Recherche pour le Développement ( IRD ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Ecole Nationale Supérieure de Chimie de Paris- Chimie ParisTech-PSL ( ENSCP ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut de Recherche pour le Développement ( IRD ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Aix Marseille Université (AMU)-Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-IMAG-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-IMAG-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Lariboisière-IFR6, Université de Brest (UBO), Institut National de la Santé et de la Recherche Médicale (INSERM)-Ecole Nationale Supérieure de Chimie de Paris- Chimie ParisTech-PSL (ENSCP)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Ecole Nationale Supérieure de Chimie de Paris- Chimie ParisTech-PSL (ENSCP)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Paris Descartes - Paris 5 (UPD5)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Université Paris 13 (UP13)-Institut National de la Recherche Agronomique (INRA)-Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)
Subjects: MESH : Transcription Factors, [SDV]Life Sciences [q-bio], Genome-wide association study, 030204 cardiovascular system & hematology, MESH : Chromosomes, Human, Pair 6, 0302 clinical medicine, Genetics(clinical), Genetics (clinical), Genetics, Venous Thrombosis, 0303 health sciences, MESH: Polymorphism, Single Nucleotide, MESH : Polymorphism, Single Nucleotide, MESH: Genetic Predisposition to Disease, MESH: Follow-Up Studies, MESH: Transcription Factors, MESH : Venous Thrombosis, MESH: Case-Control Studies, DNA-Binding Proteins, Chromosomes, Human, Pair 6, MESH : DNA-Binding Proteins, Erratum, MESH : Genome-Wide Association Study, MESH : Case-Control Studies, MESH: Chromosomes, Human, Pair 6, Locus (genetics), Biology, Polymorphism, Single Nucleotide, Genetic determinism, 03 medical and health sciences, Report, Genetic predisposition, Humans, Genetic Predisposition to Disease, Allele, Gene, 030304 developmental biology, MESH: Humans, [ SDV ] Life Sciences [q-bio], MESH : Humans, linking inflammation protein atherothrombosis sequence risk, Case-control study, Chromosome, MESH : Follow-Up Studies, Case-Control Studies, MESH: Genome-Wide Association Study, MESH: Venous Thrombosis, MESH : Genetic Predisposition to Disease, 030217 neurology & neurosurgery, MESH: DNA-Binding Proteins, Follow-Up Studies, Genome-Wide Association Study, Transcription Factors
Abstract: International audience; To identify genetic susceptibility factors conferring increased risk of venous thrombosis (VT), we conducted a multistage study, following results of a previously published GWAS that failed to detect loci for developing VT. Using a collection of 5862 cases with VT and 7112 healthy controls, we identified the HIVEP1 locus on chromosome 6p24.1 as a susceptibility locus for VT. Indeed, the HIVEP1 rs169713C allele was associated with an increased risk for VT, with an odds ratio of 1.20 (95% confidence interval 1.13-1.27, p = 2.86 x 10(-9)). HIVEP1 codes for a protein that participates in the transcriptional regulation of inflammatory target genes by binding specific DNA sequences in their promoter and enhancer regions. The current results provide the identification of a locus involved in VT susceptibility that lies outside the traditional coagulation/fibrinolysis pathway.
Published: 2010

26. Adrenergic receptor polymorphisms and platelet reactivity after treatment with dual antiplatelet therapy with aspirin and clopidogrel in acute coronary syndrome

Author: Michalis Hamilos, Corinne Frere, Emanuele Barbato, Noémie Saut, Mark Eijgelsheim, Jean Louis Bonnet, William Wijns, Leen Delrue, Thomas Cuisset, Jozef Bartunek, Katia M.C. Verhamme, Marie-Christine Alessi, Cuisset, T., Hamilos, M., Delrue, L., Frere, C., Verhamme, K., Bartunek, J., Saut, N., Bonnet, J. L., Eijgelsheim, M., Wijns, W., Alessi, M. C., and Barbato, Emanuele
Subjects: Male, Platelet Aggregation, arginine, acetylsalicylic acid, beta 2 adrenergic receptor, clopidogrel, vasodilator stimulated phosphoprotein, acute coronary syndrome, adult, aged, article, controlled study, DNA polymorphism, female, human, major clinical study, male, priority journal, protein phosphorylation, screening test, thrombocyte aggregation, treatment outcome, Acute Coronary Syndrome, Adenosine Diphosphate, Aged, Aspirin, Cell Adhesion Molecules, Chi-Square Distribution, Drug Therapy, Combination, Female, Gene Frequency, Genotype, Humans, Linear Models, Microfilament Proteins, Middle Aged, Phenotype, Phosphoproteins, Phosphorylation, Platelet Aggregation Inhibitors, Platelet Function Tests, Polymorphism, Single Nucleotide, Prospective Studies, Receptors, Adrenergic, alpha-2, beta-2, Ticlopidine, Treatment Outcome, Antiplatelet agents, Coronary syndrome, Single nucleotide polymorphisms, Platelet, Receptor, biology, Hematology, Clopidogrel, Enzyme inhibitor, Phosphoprotein, Linear Model, Drug Therapy, Combination, medicine.drug, Acute coronary syndrome, medicine.medical_specialty, Adrenergic receptor, Antiplatelet agent, Single-nucleotide polymorphism, Polymorphism, Single Nucleotide, Receptors, Adrenergic, alpha-2, Internal medicine, medicine, business.industry, Platelet Aggregation Inhibitor, vasodilator stimulated phosphoprotein, acute coronary syndrome, Microfilament Protein, medicine.disease, Platelet Function Test, Prospective Studie, Endocrinology, Cell Adhesion Molecule, biology.protein, Receptors, Adrenergic, beta-2, business, treatment outcome, Acute Coronary Syndrome
Abstract: SummaryPlatelet response to clopidogrel shows inter-individual variability that is partially explained by genetic polymorphisms. This variability affects clinical outcome when clopidogrel is administered in patients with acute coronary syndrome (ACS). Catecholamines, released during ACS, contribute to platelet aggregation through platelet α2A- (α2A-AR) and β2-adrenergic receptor (β2-AR) stimulation. It was the objective of this study to assess the potential influence of α2A-AR and β2-AR gene polymorphisms on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel in ACS. We screened 641 ACS patients for 6.3/6.7 kb α2A-AR polymorphism, and for Arg16Gly and Gln27Glu β2-AR polymorphism. After 600 mg clopidogrel, we assessed ADP 10 μmol-induced platelet aggregation (ADP-Ag) and vasoactive stimulated phosphoprotein (VASP). All single nucleotide polymorphisms were in Hardy-Weinberg equilibrium. A slight though negligible association was found between 6.3 kb allele of α2A-AR with platelet reactivity ADPAg induced (beta: –2.91 [-5.68;-0.14], p=0.04). A borderline not significant reduction in PRI VASP was observed in 6.3 kb α2A-AR carriers (beta: –3.81 [-0.09;7.72], p=0.06). No significant effect on platelet parameters was observed for the other tested polymorphisms. Common α2A- and β2-adrenergic receptor polymorphisms do not show any major impact on residual platelet reactivity in non-ST-elevation ACS when a dual antiplatelet therapy with 250 mg aspirin and 600 mg clopidogrel is administered.
Published: 2010

27. C4BPB/C4BPA is a new susceptibility locus for venous thrombosis with unknown protein S-independent mechanism: results from genome-wide association and gene expression analyses followed by case-control studies

Author: Alfonso Buil, David-Alexandre Trégouët, Juan Carlos Souto, Noémie Saut, Marine Germain, Maxime Rotival, Laurence Tiret, Françcois Cambien, Mark Lathrop, Tanja Zeller, Marie-Christine Alessi, Santiago Rodriguez de Cordoba, Thomas Münzel, Philipp Wild, Jordi Fontcuberta, France Gagnon, Joseph Emmerich, Laura Almasy, Stefan Blankenberg, José-Manuel Soria, and Pierre-Emmanuel Morange
Subjects: Male, Immunology, Single-nucleotide polymorphism, Genome-wide association study, Locus (genetics), Thrombophilia, Biochemistry, Polymorphism, Single Nucleotide, Protein S, Risk Factors, Histocompatibility Antigens, Medicine, Humans, Genetic Predisposition to Disease, Allele, Genetics, Venous Thrombosis, Clinical Trials as Topic, biology, business.industry, C4b-binding protein, Complement C4b-Binding Protein, Case-control study, Cell Biology, Hematology, medicine.disease, PS-independent, protein (C4BP), Gene Expression Regulation, Genetic Loci, Case-Control Studies, protein S (PS), biology.protein, Female, business, Genome-Wide Association Study
Abstract: 3 Figures. 2 Tables. The online version of this article contains a data supplement., Through its binding with protein S (PS), a key element of the coagulation/fibrinolysis cascade, the C4b-binding protein (C4BP) has been hypothesized to be involved in the susceptibility to venous thrombosis (VT). To identify genetic factors that may influence the plasma levels of the 3 C4BP existing isoforms, α7β1, α6β1, and α7β0, we conducted a genome-wide association study by analyzing 283 437 single nucleotide polymorphisms (SNPs) in the Genetic Analysis of Idiopathic Thrombophilia (GAIT) study composed of 352 persons. Three SNPs at the C4BPB/C4BPA locus were found genome-wide significantly associated with α7β0 levels. One of these SNPs was further found to explain approximately 11% of the variability of mRNA C4BPA expression in the Gutenberg Heart Study composed of 1490 persons, with no effect on C4BPB mRNA expression. The allele associated with increased α7β0 plasma levels and increased C4BPA expression was further found associated with increased risk of VT (odds ratio [OR] = 1.24 [1.03-1.53]) in 2 independent case-control studies (MARseille THrombosis Association study [MARTHA] and FActeurs de RIsque et de récidives de la maladie thromboembolique VEineuse [FARIVE]) gathering 1706 cases and 1379 controls. This SNP was not associated with free PS or total PS. In conclusion, we observed strong evidence that the C4BPB/C4BPA locus is a new susceptibility locus for VT through a PS-independent mechanism that remains to be elucidated., National Institutes of Health, PI-08/0420, PI-08/0756, SAF2008/01859, and Spanish Society on Thrombosis and Hemostasia (SETH). The FARIVE study was supported by grants from the Fondation pour la Recherche Médicale, the Program Hospitalier de recherche Clinique, the Fondation de France, and the Leducq Foundation. The MARTHA study was supported by a grant from the Program Hospitalier de la Recherche Clinique. The Gutenberg Heart Study is funded through the government of Rheinland-Pfalz (Stiftung Rheinland Pfalz für Innovation, contract no. AZ 961-386261/733), the research programsWissen schafft Zukunft and Schwerpunkt Vaskula¨re Prävention of the Johannes Gutenberg-University of Mainz and its contract with Boehringer Ingelheim and PHILIPS Medical Systems including an unrestricted grant for the Gutenberg Heart Study. Specifically, the research reported in this article was supported by the National Genome Network NGFNplus (contract no. project A3 01GS0833) by the Federal Ministry of Education and Research, Germany. J.-M.S. was supported by Programa d’Estabilització d’Investigadors de la Direcció d’Estrategia i Coordinació del Departament de Salut (Generalitat de Catalunya); M.G., by a grant funded by the Agence Nationale pour la Recherche (Project ANR-07-MRAR-021). F.G. holds a Canada Research Chair.
Published: 2010

28. Polymorphisms of the lamina maturation pathway and their association with the metabolic syndrome: the DESIR prospective study

Author: Anne Dutour, Nicolas Lévy, B. Balkau, Pierre-Emmanuel Morange, Marie-Christine Alessi, Catherine Badens, Michel Marre, Irène Juhan-Vague, Jean Tichet, David-Alexandre Trégouët, Noémie Saut, Bénédicte Fontaine-Bisson, and Frédéric Fumeron
Subjects: Adult, Male, Single-nucleotide polymorphism, Biology, Polymorphism, Single Nucleotide, LMNA, Drug Discovery, Genotype, medicine, Humans, Genetic Predisposition to Disease, Prospective Studies, Genetics (clinical), Genetic association, Aged, Genetics, Metabolic Syndrome, integumentary system, Haplotype, Proteins, Middle Aged, medicine.disease, Lamin Type A, Human genetics, Lamins, Molecular Medicine, Female, France, Metabolic syndrome, Lamin
Abstract: Laminopathies are rare monogenic diseases, some of them exhibiting features of the metabolic syndrome. These diseases are mainly due to mutations in LMNA, encoding A-type lamins. One LMNA polymorphism, rs4641, has been associated with the metabolic syndrome, but results have been controversial. We therefore investigated the effect of single nucleotide polymorphisms (SNPs) in the LMNA gene in combination with four other genes encoding enzymes influencing lamin post-translational maturation on risk of metabolic syndrome (MS). Twenty-three tagging SNPs characterising the haplotypic variability of five genes (LMNA, ICMT, ZMPSTE24, FNTA and FNTB) were genotyped in 3,916 French men and women who took part in the prospective DESIR study. Single locus and haplotype analyses were performed but did not detect any significant association with the risk of MS. No robust interaction between SNPs located in different genes on the risk of MS was identified. In conclusion, we did not observe any convincing evidence that common polymorphisms of the lamina pathway could modulate the risk of MS.
Published: 2009

29. TAFI antigen level variability in young healthy Asian Indians; first report from Asia

Author: Madhuri Behari, Renu Saxena, Corinne Frere, Suhail Akhter, Noémie Saut, Arijit Biswas, Ravi Ranjan, Deepak Kumar Shukla, Arvind Meena, and Irene Juhan Vague
Subjects: Adult, Male, Carboxypeptidase B2, Adolescent, medicine.medical_treatment, Coefficient of variation, Clinical Biochemistry, Population, India, Fibrin, Thrombin, Antigen, Asian People, Fibrinolysis, medicine, Humans, education, Child, education.field_of_study, biology, Chemistry, Genetic Variation, General Medicine, Blood proteins, Child, Preschool, Immunology, biology.protein, Fibrinolytic inhibitor, Female, medicine.drug
Abstract: Thrombin Activatable Fibrinolytic Inhibitor (TAFI) is a plasma protein, which inhibits fibrinolysis by removing carboxyterminal lysine residues from partially degraded fibrin thereby decreasing plasminogen binding on its surface. In this study we have investigated the antigenic level variability (Inter and Intraindividual) of Thrombin Activatable Fibrinolysis Inhibitor in 120 healthy Asian Indians since no data on this is available regarding this population. TAFI antigen levels did not show a normal distribution in our population (p0.001). Median TAFI antigen levels were found to be 11.683 microg/ml. It ranged from 33.9-202.5%of normal pool plasma (3.9-23.5 microg/ml). TAFI antigenic level showed high level of variability in the Indian population (coefficient of variation: 37.4%). TAFI antigenic levels were stable intraindividually (p=0.218).
Published: 2007

30. Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study

Author: David-Alexandre Trégouët, Corinne Frere, Noémie Saut, Pierre-Emmanuel Morange, Laurence Tiret, Marie-Christine Alessi, Dinar Kouassi, and Irène Juhan-Vague
Subjects: Adult, Male, Linkage disequilibrium, Genotype, Immunology, Quantitative Trait Loci, Black People, Single-nucleotide polymorphism, Blood Donors, Biology, Quantitative trait locus, Biochemistry, Linkage Disequilibrium, White People, Phylogenetics, SNP, Humans, Gene, 3' Untranslated Regions, Histone Acetyltransferases, Genetics, TATA-Binding Protein Associated Factors, Polymorphism, Genetic, Haplotype, Chromosome Mapping, Promoter, Cell Biology, Hematology, Cote d'Ivoire, Female, Transcription Factor TFIID, France, 5' Untranslated Regions
Abstract: Recent studies revisiting the association between plasma thrombin-activatable fibrinolysis inhibitor (TAFI) Ag levels and polymorphisms of the CPB2 gene (coding for TAFI) suggested that TAFI Ag levels were influenced by 2 major quantitative trait nucleotides (QTNs) in European whites. However, the strong linkage disequilibrium (LD) between CPB2 polymorphisms in European whites did not allow one to distinguish which polymorphisms could be the putative QTNs. To get a better insight into the identification of QTNs, a transethnic haplotype analysis contrasting 2 populations of African and European subjects was performed using 13 CPB2 polymorphisms. Results of the haplotype analyses suggested that 3 QTNs had independent effects and explained about 15% of the TAFI variability, consistently in the 2 populations. The lower LD observed in the African population enabled us to identify the 1583T>A SNP located in 3′UTR as one of these QTNs, whereas the -2599C>G and -2345--2344insG SNPs located in the 5′ region might be the 2 other QTNs. A phylogenetic study suggested that these 3 polymorphisms occurred before the period of migration “out of Africa.” Although this transethnic comparison contributed to better map the putative CPB2 QTNs, further studies are required to clarify the role of the promoter region.
Published: 2006

31. TLR4/Asp299Gly, CD14/C-260T, plasma levels of the soluble receptor CD14 and the risk of coronary heart disease: The PRIME Study

Author: Pierre Morange, Gérald Luc, Jean Ferrières, F. Cambien, Laurence Tiret, P. Amouyel, Pierre Ducimetière, Noémie Saut, Alun Evans, Irène Juhan-Vague, and Dominique Arveiler
Subjects: medicine.medical_specialty, Population, Lipopolysaccharide Receptors, Coronary Disease, Receptors, Cell Surface, Biology, Genetic determinism, Pathogenesis, Risk Factors, Internal medicine, Blood plasma, Genetics, medicine, Humans, Point Mutation, Allele, education, Prospective cohort study, Receptor, Genetics (clinical), Inflammation, education.field_of_study, Membrane Glycoproteins, Polymorphism, Genetic, Toll-Like Receptors, Toll-Like Receptor 4, Endocrinology, Amino Acid Substitution, TLR4, Endothelium, Vascular, Biomarkers, Signal Transduction
Abstract: TLR4 and CD14 are two components of the LPS receptor complex, which are considered to play a key role in the pathogenesis of atherosclerosis. TLR4/Asp299Gly and CD14/C-260T polymorphisms are thought to modulate the activity of this complex. The aim of the study was to examine the association between the TLR4/Asp299Gly and CD14/C-260T polymorphisms, plasma levels of the soluble receptor CD14 (sCD14), and the incidence of coronary heart disease (CHD) in a prospective cohort (the PRIME Study) of 9758 healthy men aged 50-59 years recruited in France and Northern Ireland. A nested case-control design was used, comparing the 249 participants who developed a CHD event during the 5-year follow-up with 492 population- and age-matched control subjects. The two polymorphisms were genotyped and baseline plasma concentrations of sCD14 were measured. None of the two polymorphisms, or sCD14 levels, either considered alone or in combination, were associated with the risk of CHD. The CD14/C-260T allele was associated with increased plasma concentrations of soluble thrombomodulin and vascular cell adhesion molecule-1 and, to a lesser extent, sCD14. No relationship was observed between the TLR4 polymorphism and, any of the inflammatory and endothelial markers measured. The TLR4/Asp299Gly and CD14/C-260T polymorphisms and plasma sCD14 concentrations do not appear as significant predictors of the risk of CHD in healthy individuals.
Published: 2004

32. Sequence family variant loss from the AZFc interval of the human Y chromosome, but not gene copy loss, is strongly associated with male infertility

Author: A. Navarro, Christophe Chevillard, Ken McElreavey, M.-G. Mattei, J Belougne, Mj Mitchell, N Machev, P Collignon, Jacques Chiaroni, Nicolas Lévy, E Clemente, Catherine Metzler-Guillemain, Am Frances, Noémie Saut, Marie-Roberte Guichaoua, C Durand, Axel Ducourneau, P. Terriou, N Pech, Guy Longepied, Instituto de Sistemas Optoelectrónicos y Microtecnología, Universidad Politécnica de Madrid (UPM), Service de Génétique, Centre Hospitalier de toulon, Etablissement Français du Sang - Alpes-Méditerranée (EFS - Alpes-Méditerranée), Etablissement Français du Sang, Anthropologie bio-culturelle, Droit, Ethique et Santé (ADES), Aix Marseille Université (AMU)-EFS ALPES MEDITERRANEE-Centre National de la Recherche Scientifique (CNRS), Institut de Biologie du Développement de Marseille (IBDM), and Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Male, Infertility, Unequal crossing over, Gene Conversion, Gene Dosage, Biology, Y chromosome, Gene dosage, Male infertility, 03 medical and health sciences, 0302 clinical medicine, Genetics, medicine, Humans, Genetic Predisposition to Disease, In Situ Hybridization, Fluorescence, Genetics (clinical), ComputingMilieux_MISCELLANEOUS, 030304 developmental biology, Chromosomal inversion, Recombination, Genetic, 0303 health sciences, Azoospermia factor, Chromosomes, Human, Y, Polymorphism, Genetic, 030219 obstetrics & reproductive medicine, Base Sequence, Genetic Variation, Nuclear Proteins, RNA-Binding Proteins, Deleted in Azoospermia 1 Protein, Oligospermia, medicine.disease, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, Chromosome Inversion, Original Article, Gene Deletion
Abstract: Background: Complete deletion of the complete AZFc interval of the Y chromosome is the most common known genetic cause of human male infertility. Two partial AZFc deletions (gr/gr and b1/b3) that remove some copies of all AZFc genes have recently been identified in infertile and fertile populations, and an association study indicates that the resulting gene dose reduction represents a risk factor for spermatogenic failure. Methods: To determine the incidence of various partial AZFc deletions and their effect on fertility, we combined quantitative and qualitative analyses of the AZFc interval at the DAZ and CDY1 loci in 300 infertile men and 399 control men. Results: We detected 34 partial AZFc deletions (32 gr/gr deletions), arising from at least 19 independent deletion events, and found gr/gr deletion in 6% of infertile and 3.5% of control men (p>0.05). Our data provide evidence for two large AZFc inversion polymorphisms, and for relative hot and cold spots of unequal crossing over within the blocks of homology that mediate gr/gr deletion. Using SFVs (sequence family variants), we discriminate DAZ1/2, DAZ3/4, CDY1a (proximal), and CDY1b (distal) and define four types of DAZ-CDY1 gr/gr deletion. Conclusions: The only deletion type to show an association with infertility was DAZ3/4-CDY1a (p = 0.042), suggesting that most gr/gr deletions are neutral variants. We see a stronger association, however, between loss of the CDY1a SFV and infertility (p = 0.002). Thus, loss of this SFV through deletion or gene conversion could be a major risk factor for male infertility.
Published: 2004

33. First case of a humanRASGRP2mutation affecting Rap1 activation in platelets and causing severe bleeding

Author: Pierre Morange, Marie-Christine Alessi, François Cambien, Hana Raslova, Charlotte Grosdidier, Noémie Saut, Taco W. Kuijpers, Alan T. Nurden, Nadjim Chelghoum, Marine Germain, Xavier Pillois, Marie Guinier, David-Alexandre Trégouët, Franck Peiretti, Matthias Canault, Anne Pierres, Dorsaf Ghalloussi, Claire Perret, and Timo K. van den Berg
Subjects: Severe bleeding, Mutation (genetic algorithm), Cancer research, Platelet, Rap1, Cell Biology, Biology
Published: 2014

34. A Y-encoded subunit of the translation initiation factor Eif2 is essential for mouse spermatogenesis

Author: Áine Rattigan, Vladimir Grigoriev, Paul S. Burgoyne, Eva M. Eicher, Michael J. Mitchell, Obah A. Ojarikre, Colin E. Bishop, Shantha K. Mahadevaiah, Sophie Mazeyrat, and Noémie Saut
Subjects: Genetics, Male, eIF2, Reverse Transcriptase Polymerase Chain Reaction, Eukaryotic Initiation Factor-2, Mice, Transgenic, Biology, Y chromosome, Mice, Inbred C57BL, Mice, Eukaryotic translation, Prophase, USP9Y, Initiation factor, Animals, Translation factor, Transgenes, Spermatogenesis, Gene, Sequence Deletion
Abstract: In mouse and man, deletions of specific regions of the Y chromosome have been linked to early failure of spermatogenesis and consequent sterility; the Y chromosomal gene(s) with this essential early role in spermatogenesis have not been identified. The partial deletion of the mouse Y short arm (the Sxrb deletion) that occurred when Tp(Y)1CtSxr-b (hereafter Sxrb) arose from Tp(Y)1CTSxr-b (hereafter Sxra) defines Spy, a Y chromosomal factor essential for normal spermatogonial proliferation. Molecular analysis has identified six genes that lie within the deletion: Ube1y1 (refs. 4,5), Smcy, Uty, Usp9y (also known as Dffry), Eif2s3y (also known as Eif-2gammay) and Dby10; all have closely similar X-encoded homologs. Of the Y-encoded genes, Ube1y1 and Dby have been considered strong candidates for mouse Spy function, whereas Smcy has been effectively ruled out as a candidate. There is no Ube1y1 homolog in man, and DBY, either alone or in conjunction with USP9Y, is the favored candidate for an early spermatogenic role. Here we show that introduction of Ube1y1 and Dby as transgenes into Sxrb-deletion mice fails to overcome the spermatogenic block. However, the introduction of Eif2s3y restores normal spermatogonial proliferation and progression through meiotic prophase. Therefore, Eif2s3y, which encodes a subunit of the eukaryotic translation initiation factor Eif2, is Spy.
Published: 2001

35. RBMY evolved on the Y chromosome from a ubiquitously transcribed X-Y identical gene

Author: Noémie Saut, Michael J. Mitchell, Sophie Mazeyrat, and Marie-Geneviève Mattei
Subjects: Genetics, Male, X Chromosome, Base Sequence, Biology, Y chromosome, Biological Evolution, Mice, Y Chromosome, Testis, Animals, Humans, Female, Gene, In Situ Hybridization, Fluorescence, DNA Primers
Published: 1999

36. The mouse Y chromosome interval necessary for spermatogonial proliferation is gene dense with syntenic homology to the human AZFa region

Author: Andy Greenfield, Guy Longepied, Nabeel A. Affara, Carole A. Sargent, Ingrid Ehrmann, Michael J. Mitchell, Sophie Mazeyrat, Pamela Ellis, Sean M. Grimmond, and Noémie Saut
Subjects: Male, Transcription, Genetic, Ubiquitin-Protein Ligases, Molecular Sequence Data, Kruppel-Like Transcription Factors, Biology, Y chromosome, Homology (biology), DEAD-box RNA Helicases, Ligases, Minor Histocompatibility Antigens, Exon, Mice, Exon trapping, Gene mapping, Y Chromosome, Genetics, Animals, Chromosomes, Human, Humans, Spermatogenesis, Molecular Biology, Genetics (clinical), X chromosome, Genomic organization, Contig, Chromosome Mapping, Nuclear Proteins, Proteins, General Medicine, Exons, Chromosomes, Bacterial, Rats, DNA-Binding Proteins, Mice, Inbred C57BL, Female, Transcription Factors
Abstract: The Delta Sxrb deletion interval of the mouse Y chromosome contains Spy, a spermatogenesis factor gene(s) whose expression is essential for the postnatal development of the mitotic germ cells, spermatogonia. The boundaries of Delta Sxrb are defined by the duplicated genes Zfy1 and Zfy2 and four further genes have previously been mapped within the interval: Ube1y and Smcy, linked with Zfy1 on a contig of 250 kb, and Dffry and Uty, which were unanchored. The interval was estimated to be >450 kb. In order to identify any further gene(s) that may underlie Spy, systematic exon trapping was performed on an extended contig, anchored on Zfy1, which covers 750 kb of the Delta Sxrb interval. Exons from two novel genes were isolated and placed together with Dffry and Uty on the contig in the order Dffry-Dby-Uty-Tspy-Eif2gammay-Smcy- Ube1y-Zfy1. All the genes, with the double exception of Tspy, are X-Y homologous and produce putatively functional, spliced transcripts. The tight linkage and order of Dffry, Dby and Uty was shown to be conserved in deletion intervals 5C/5D of the human Y chromosome by the construction of a contig of human PAC and YAC clones; this represents the first example of syntenic homology between Y chromosomes from two distinct mammalian orders. Interval 5C/5D contains the distal boundary of the AZFa interval, which, like Delta Sxrb, is believed to be necessary for spermatogonial development in the prepubertal testis. Our results therefore show that AZFa and Spy may be encoded by homologous genes.
Published: 1998

37. Caution in Interpreting Results from Imputation Analysis When Linkage Disequilibrium Extends over a Large Distance: A Case Study on Venous Thrombosis

Author: Philippe Amouyel, Joseph Emmerich, Marie-Christine Alessi, François Cambien, Diana Zelenika, Anne-Marie Dupuy, Laurence Tiret, Tiphaine Oudot-Mellakh, Pierre-Emmanuel Morange, Marine Germain, Marion Bertrand, Noémie Saut, David-Alexandre Trégouët, Jean-Charles Lambert, Mark Lathrop, and Luc Letenneur
Subjects: Linkage disequilibrium, Statistics as Topic, lcsh:Medicine, Genome-wide association study, Locus (genetics), Biology, Cardiovascular, Polymorphism, Single Nucleotide, Linkage Disequilibrium, Gene Frequency, Risk Factors, Genome Analysis Tools, Genome-Wide Association Studies, Genetics, Humans, Genetic Predisposition to Disease, 1000 Genomes Project, lcsh:Science, Genetic Association Studies, Genetic association, Venous Thrombosis, Multidisciplinary, Coagulation Disorders, Genome, Human, lcsh:R, Haplotype, Computational Biology, Human Genetics, Genomics, Venous Thromboembolism, Hematology, Tag SNP, Haplotypes, Case-Control Studies, Mutation, Genetics of Disease, Medicine, lcsh:Q, Imputation (genetics), Genome-Wide Association Study, Research Article
Abstract: By applying an imputation strategy based on the 1000 Genomes project to two genome-wide association studies (GWAS), we detected a susceptibility locus for venous thrombosis on chromosome 11p11.2 that was missed by previous GWAS analyses that had been conducted on the same datasets. A comprehensive linkage disequilibrium and haplotype analysis of the whole locus where twelve SNPs exhibited association p-values lower than 2.23 10(-11) and the use of independent case-control samples demonstrated that the culprit variant was a rare variant located ~1 Mb away from the original hits, not tagged by current genome-wide genotyping arrays and even not well imputed in the original GWAS samples. This variant was in fact the rs1799963, also known as the FII G20210A prothrombin mutation. This work may be of major interest not only for its scientific impact but also for its methodological findings.
Published: 2012

38. Genetics of Venous Thrombosis: Insights from a New Genome Wide Association Study

Author: Mark Lathrop, David-Alexandre Trégouët, Pierre-Emmanuel Morange, Jean-Charles Lambert, Philippe Amouyel, Joseph Emmerich, Marion Bertrand, Anne-Marie Dupuy, Christian Dina, Diana Zelenika, Nicolas Greliche, Marine Germain, Luc Letenneur, François Cambien, Tiphaine Oudot-Mellakh, Claire Perret, William Cohen, Noémie Saut, Guillemette Antoni, Marie-Christine Alessi, and Laurence Tiret
Subjects: Heredity, Genotypes, lcsh:Medicine, Single-nucleotide polymorphism, Genome-wide association study, Disease, Biology, Cardiovascular, Polymorphism, Single Nucleotide, Genome, Genome Analysis Tools, Vascular Biology, Genetic variation, Genome-Wide Association Studies, Genetics, Genetic predisposition, Humans, Genetic Predisposition to Disease, lcsh:Science, Genetic Association Studies, Aged, Venous Thrombosis, Evolutionary Biology, Multidisciplinary, Population Biology, Complex Traits, lcsh:R, Haplotype, Case-control study, Computational Biology, Human Genetics, Genomics, Venous Thromboembolism, Hematology, Haplotypes, Case-Control Studies, Sample Size, Genetics of Disease, Genetic Polymorphism, Epistasis, Medicine, lcsh:Q, Population Genetics, Research Article, Genome-Wide Association Study
Abstract: Background: Venous Thrombosis (VT) is a common multifactorial disease associated with a major public health burden. Genetics factors are known to contribute to the susceptibility of the disease but how many genes are involved and their contribution to VT risk still remain obscure. We aimed to identify genetic variants associated with VT risk. Methodology/Principal Findings: We conducted a genome-wide association study (GWAS) based on 551,141 SNPs genotyped in 1,542 cases and 1,110 controls. Twelve SNPs reached the genome-wide significance level of 2.0×10−8 and encompassed four known VT-associated loci, ABO, F5, F11 and FGG. By means of haplotype analyses, we also provided novel arguments in favor of a role of HIVEP1, PROCR and STAB2, three loci recently hypothesized to participate in the susceptibility to VT. However, no novel VT-associated loci came out of our GWAS. Using a recently proposed statistical methodology, we also showed that common variants could explain about 35% of the genetic variance underlying VT susceptibility among which 3% could be attributable to the main identified VT loci. This analysis additionally suggested that the common variants left to be identified are not uniformly distributed across the genome and that chromosome 20, itself, could contribute to ∼7% of the total genetic variance. Conclusions/Significance: This study might also provide a valuable source of information to expand our understanding of biological mechanisms regulating quantitative biomarkers for VT.
Published: 2011

39. R-166. Molecular diagnosis of Y chromosome deletions in infertile patients with reduced sperm production

Author: Noémie Saut, M. Devictor, Catherine Metzler-Guillemain, Michael J. Mitchell, P. Terriou, Nicolas Lévy, and A. Navarro
Subjects: Genetics, Reproductive Medicine, Y chromosome deletions, Rehabilitation, Obstetrics and Gynecology, Biology, Spermatogenesis
Published: 1999

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

39 results on '"Noémie Saut"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources